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Abstract 
N-methyl D-aspartate (NMDA) receptors are calcium permeable, glutamate-
gated ion channels that mediate many forms of synaptic plasticity in the central 
nervous system. Due to their pivotal role in regulating synaptic plasticity, a 
canonical correlate of the molecular and cellular basis for learning and memory, 
they are implicated in the pathophysiology of various neurological disorders. 
Recently, advances in genome sequencing has identified the NMDA receptor to 
be intolerant to genetic variation, as variation often leads to disease. For 
example, mutations in the GluN2A subunit of the NMDA receptor are implicated 
in the etiology of severe epilepsy-aphasia spectrum disorders. Here we selected 
six gain-of-function mutations identified in patients with epilepsy-aphasia 
spectrum disorders and characterized their sensitivity to inhibition by GluN2A-
selective negative allosteric modulators. We found that GluN2A-selective 
negative allosteric modulators can inhibit all the GluN2A gain-of-function-
containing NMDA receptors tested, despite the location of the mutation in the 
receptor. However, we also found no clear evidence that transfection of GluN2A 
gain-of-function mutations is toxic or causes overt hyperexcitability in cultured 
cortical neurons or CA1 pyramidal neurons of the hippocampus. These data 
indicate that while GluN2A-selective negative allosteric modulators can inhibit 
NMDA receptors harboring GluN2A gain-of-function mutations, the presence of 
mutated GluN2A may not directly cause cell toxicity or hyperexcitability, at least 
in cultured neuronal systems.  
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Negative allosteric modulation of NMDA 
receptors with GluN2A gain-of-function 
mutations 
1.0 General introduction to chemical neurotransmission 
The primary mode of intercellular communication in the central nervous system is 
defined as electrochemical neurotransmission. This mode of communication is unique 
to the cells of our nervous system and is responsible for translating our experiences into 
quantifiable cellular and molecular phenomena. As its name implies, electrochemical 
transmission encodes information by use of both chemical flux as well as generation of 
electrical potential changes within and around cells. 
The general flow of electrochemical neurotransmission proceeds as follows: A 
chemical message released from the axon terminal of a pre-synaptic neuron reaches 
the receiving, post-synaptic neuron to activate transmembrane proteins. These post-
synaptic proteins translate the neurotransmitter signature into an electrical current which 
can spread throughout the receiving neuron. Once the propagating current reaches the 
axon terminal, the message is converted back into a chemical code to continue the 
spread of information. 
While neurotransmission is controlled by various neurotransmitter types, the two 
primary drivers are glutamate and gamma-aminobutyric acid (GABA), which together 
largely drive excitatory and inhibitory neurotransmission, respectively. Maintaining the 
proper balance of excitatory and inhibitory neurotransmission is pivotal to sustaining a 
healthy nervous system, and unsurprisingly, neurological disorders can result when 
excitation or inhibition is skewed in any direction. For example, if the nervous system is 
too excitable, synchronous, electrical discharges could accumulate and cause 
epileptiform activity. Alternatively, inhibitory tone could dominate and result in whole 
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organism sedation, as seen with barbiturate administration. Chronic imbalances in 
excitatory and inhibitory neurotransmission can essentially rewire the brain and lead to 
neuropsychiatric disorders, like schizophrenia. Recent evidence indicates that 
schizophrenia is a manifestation of a chronic increase in inhibitory tone (for more detail 
the reader is referred to the section on NMDA receptors in disease). 
This dissertation primarily focuses on a subset of mutations that perturb the 
excitatory/inhibitory balance. Consequences of this shift spans disruptions in 
neurodevelopment and synaptic plasticity homeostasis, causing detrimental outcomes 
including epilepsy (Addis et al., 2017; Chen et al., 2017; Endele et al., 2010; Yuan et al., 
2014; Gao et al., 2017; Ogden et al., 2017; Xu et al., 2018). Herein, we characterize 
these mutations in various model systems and assess potential amelioration with 
selective pharmacological tools.  
1.1 Ionotropic glutamate receptors and synaptic transmission 
Ionotropic glutamate receptors (iGluRs) are the primary drivers of glutamatergic 
excitatory transmission and inherently play major roles in dictating the stability of the 
excitatory/inhibitory balance. The iGluRs are ubiquitously expressed glutamate-gated 
cation channels and are subcategorized into three groups: AMPA, kainate, and NMDA 
receptors (Review - Traynelis et al., 2010). Both AMPA and kainate receptors modulate 
fast monovalent excitatory neurotransmission but have different expression profiles. 
While AMPA receptors are universally expressed throughout the CNS, kainate receptor 
expression is more discretely localized, with greatest expression in the cortex, striatum, 
and hippocampus (Bahn et al., 1994).While NMDA receptors share a similar expression 
pattern to AMPA receptors, their requirements for activation diverge from both AMPA 
and kainate receptors. In addition to glutamate binding, NMDA receptors require 
simultaneous binding of glutamate and a co-agonist, glycine or D-serine, along with 
concurrent membrane depolarization to relieve tonic Mg2+-mediated inhibition (Johnson 
and Ascher, 1987; Kleckner and Dingledine, 1988; Benveniste and Mayer, 1991; 
Clements and Westbrook, 1991, 1994). When all these requirements are fulfilled, 
NMDA receptors open and mediate the influx of both mono- and divalent cations, 
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including Ca2+ (Figure 1.1) (MacDermott et al., 1986; see Traynelis et al., 2010 for 
review). 
In addition to depolarizing the surrounding dendrite, NMDA receptor mediated 
Ca2+ permeability promotes activation of second messenger signaling cascades 
important for transducing experiences into quantifiable differences in synaptic strength 
(i.e. synaptic plasticity) (Lisman 1987) Review - Nicoll). Apart from GluA2 subunit 
lacking AMPA receptors, both AMPA and kainate receptors are impermeable to Ca2+. In 
this respect, AMPA and kainate receptors drive postsynaptic depolarization to act as the 
first step in this NMDA receptor orchestrated coincidence detection system, where the 
final step results in NMDA receptor mediated Ca2+ influx. Ca2+ levels are tightly 
regulated in cells (Review – Clapman, 2007) and when internal concentrations diverge 
from baseline, various second messenger signaling cascades are activated to influence 
long-term potentiation (LTP) or depression (LTD) of synaptic strength (Review - Nicoll, 
2017).  
LTP and LTD describe the mode of synaptic plasticity and are largely mediated 
by NMDA receptor activity. Upon NMDA receptor mediated Ca2+ influx, downstream 
targets are activated, and synaptic refinement commences. Acute fluxes of highly 
concentrated Ca2+ waves generally lead to LTP, whereas slow, more diffuse Ca2+ influx 
dictates LTD (Luscher and Malenka, 2012; Review -  Nicoll, 2017). As such, LTP results 
from repetitive, high frequency stimulation that often leads to AMPA receptor 
recruitment to the synapse (Hayashi et al., 2000; Lushcer and Malenka 2012; Jurado et 
A B Figure 1.1:  Ligand binding sites and ion 
permeation in iGluRs. A) AMPA and 
kainate receptors activate upon binding of 
glutamate and are permeable to 
monovalent cations. B) NMDA receptors 
require binding of glutamate and glycine, or 
D-serine, along with concomitant 
membrane depolarization to relieve a tonic 
Mg2+ block to open the ion channel pore, 
which is permeable to both mono- and 
divalent cations. Adapted from Principles of 
Neuroscience, 5th edition, 2012. 
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al., 2013). Greater prevalence of synaptic AMPA receptors renders the postsynaptic 
dendrite more sensitive to presynaptic neurotransmitter release, and consequently more 
likely to depolarize. With a greater likelihood of depolarization, NMDA receptors are 
essentially primed for activation of further Ca2+ influx. This feed-forward cycle results in 
more AMPA receptor recruitment and an increase in synaptic surface area, as 
evidenced by the formation of mushroom spines. 
LTD results from low frequency stimulation, leading to a slow and dispersed Ca2+ 
accumulation. This more nebulous Ca2+ flux activates protein phosphatases, instead of 
kinases as with LTP, and leads to downstream signaling that promotes synaptic 
destabilization. Mechanisms of LTP and LTD are widely regarded as the cellular and 
molecular substrates for learning and memory formation, along with memory extinction, 
and are highly dependent on NMDA receptor activity (Review – Nicoll, 2017).  
1.2 Structure and functional properties of NMDA receptors  
1.2.1 NMDA receptor structure 
NMDA receptors assemble as a dimer of dimers consisting of two GluN1 
subunits complexing with either two GluN2 or GluN3 subunits (Lee and Gouaux, 2011; 
Monyer et al., 1992; Schorge and Colquhoun, 2005; Traynelis et al., 2010; Ulbrich and 
Isacoff, 2007, 2008). Finetuning of NMDA receptor responses is dictated by subunit 
composition, and this inherent functional diversity is enhanced by the various splice and 
gene variants within the individual subunits themselves. The GluN1 subunit, encoded by 
the GRIN1 gene, exists in eight different splice variants, four different GluN2 subunits 
have been identified (GluN2A-D)  encoded by distinct genes (GRIN2A-D), and  two 
different GluN3 subunits exist (GluN3A-B) encoded by two genes (GRIN3A-B). GluN1 
and GluN3 subunits bind the co-agonists glycine or D-serine, whereas GluN2 subunits 
bind glutamate.  
NMDA receptor subunits assemble in an alternating pattern (GluN1-GluN2-
GluN1-GluN2), with alike subunits arranged across from one another with two-fold 
symmetry (Figure 1.2) (Karakas and Furukawa, 2014, Riou et al., 2012). Each subunit 
has an extracellular amino-terminal domain (ATD), agonist binding domain (ABD), 
transmembrane domain (TMD), and carboxy-terminal domain (CTD). The ATD is 
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involved in NMDA receptor subunit assembly and the target of both endogenous and 
exogenous allosteric modulators (Khatri et al., 2014; Kaiser et al., 2018). The ABD is 
sculpted from two discontinuous segments of the polypeptide chain (S1 and S2) to 
resemble a clamshell that bites down upon agonist binding. The transmembrane 
domain consists of three transmembrane helices (M1, M3, and M4), which transduce 
agonist binding to channel opening, and a membrane-reentrant loop (M2) that forms a 
narrow constriction in the central ion channel pore and thereby renders the channel 
sensitive to Mg2+ block and regulates channel permeability (Schneggenburger and 
Ascher, 1997; Ren et al., 2003; Talukder et al., 2010; Kazi et al., 2013). The CTD 
extends into the cytoplasm and provides a scaffold for receptor trafficking and signal 
transduction (Aman et al., 2014; Lussier et al., 2015). As depicted in Figure 1.2, 
subunits arrange as a “dimer of dimers”, with the ATD more loosely packed and 
unfurling into the extracellular environment (Traynelis et al., 2010). 
 Crystallographic structures of NMDA receptors reveal striking similarly to AMPA 
and kainate receptors. Notably, all iGluR members arrange in a layered symmetry 
among the TMD, ABD, and ATD. The TMD adopts a quasi-four-fold symmetry and the 
extracellular ABD and ATDs assemble with a two-fold, dimer-of-dimers axis of 
symmetry (Figure 1.2) (Sobolevsky et al., 2010). Salient differences among NMDA and 
AMPA/kainate receptors are localized to the ABD and ATD domains. Comparably, 
NMDA receptors have more points of contact along the ABD interface, which creates a 
structurally established line of allosteric interaction among the ABD heterodimers 
A B Figure 1.2:  NMDA receptor domain 
symmetry. A) Structure of a GluN1/GluN2B 
NMDA receptor with domains indicated. The 
CTD is excluded. B) GluN1 and GluN2 
subunits arrange in a 1-2-1-2 alternating 
pattern in the ATD and ABD and show quasi-
four-fold symmetry in the TMD. Note that the 
1-2-1-2 arrangement interchanges between 
subdomains (i.e. subunit arrangement is 
mirrored between ATD and ABD domains). 
Adapted with modifications from Hansen et 
al., 2018. 
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(Karakas and Furukawa, 2014; Lee et al., 2014). These contacts may help explain 
glycine potency disparities among GluN2 subunits. Similarly, NMDA receptors have 
more points of interaction between the ATD-ABD interface as compared to 
AMPA/kainate receptors (Reagan et al., 2018). This results in a more compact ATD, 
resembling a hot air balloon compared to the diffuse Y-shaped ATD seen in 
AMPA/kainate receptors. This could be the reason that the ATD in NMDA receptors, but 
not AMPA receptors, harbors binding sites for allosteric modulators and is itself an 
allosteric domain that controls many biophysical properties that are different between 
the NMDA receptor subtypes. 
1.2.2 NMDA receptor function 
 Glutamate is released from presynaptic vesicles and persists in the synapse at a 
concentration of approximately 1.1mM ,which decays with a time constant of 1.2 ms 
(Clements et al., 1992). Upon presynaptic release of glutamate, AMPA/kainate 
receptors deactivate rapidly (τdeact 1-2ms), while NMDA receptors deactivate orders of 
magnitude slower (τdeact 50-500ms). This incongruity in kinetics further reinstates the 
coincidence detector nature of NMDA receptors. Due to their slow time course of 
activation and deactivation, they can integrate frequency patterns of presynaptic 
neurotransmitter release into salient signals of synaptic strength.  
NMDA receptor kinetics are controlled by agonist affinity, pre-gating steps, and 
transitions between gating states. Though desensitization plays a prominent role in 
regulating kinetic properties in AMPA/kainate receptors, desensitized NMDA receptors 
only represent a small fraction of activated receptors (Zhang et al., 2008). Instead, 
NMDA receptor kinetics are described by a series of pre-gating steps followed by 
transitions between both glutamate-bound closed and open states, until glutamate 
eventually unbinds. Upon brief exposure to glutamate, NMDA receptors proceed 
through agonist binding, pre-gating, gating, with individual transitions between these 
states, ultimately resulting in agonist unbinding over the time course of hundreds of 
milliseconds, which conveniently mirrors the  overall decay time course of excitatory 
postsynaptic currents (Lester et al., 1990; Hestrin et al., 1990; Bourne and Nicoll, 1993; 
Seeburg et al., 1995). 
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NMDA receptor heterogeneity is illustrated through the distinct temporal and 
spatial properties of GluN2 subunits. Pharmacological properties vary in deactivation 
kinetics, channel conductance, channel open probability, agonist potencies, Ca2+ 
permeability, sensitivity to Mg2+ block, and sensitivity to endogenous inhibitors (i.e. Zn2+ 
and H+) (Monyer et al., 1992; Vicini et al., 1998; Wyllie et al., 1998; Erreger et al., 2004; 
Erreger et al., 2007; Chen et al., 2008; Hansen et al., 2008; Yuan et al., 2009; Glasgow 
et al., 2015 for review). GluN2A and GluN2B containing NMDA receptors have high 
Ca2+ permeability, channel conductance, and sensitivity to Mg2+ block. Conversely, 
GluN2C and GluN2D containing NMDA receptors have lower Ca2+ permeability, 
channel conductance, and sensitivity to Mg2+. Furthermore, GluN2A containing NMDA 
receptors show the fastest deactivation kinetics, lowest agonist potencies, and greatest 
open probability, whereas GluN2B, GluN2C and GluN2D- containing NMDA receptors 
have much slower deactivation kinetics, greater affinity for agonists, and lower open 
probabilities. Binding and regulation by endogenous inhibitors are highly variable among 
subtypes, with no clear trend. GluN2A, GluN2B, and GluN2D containing NMDA 
receptors are sensitive to proton-mediated inhibition, whereas only GluN2A containing 
NMDA receptors are sensitive to Zn2+-mediated inhibition (For review see Paoletti et al., 
2013 and Glasgow et al., 2015). 
NMDA receptors are activated by the agonist glutamate and co-agonists glycine 
and D-serine. Glutamate is released pre-synaptically and is cleared from the synaptic 
space by excitatory amino acid transporters (EAATs) on a millisecond timescale 
(Danbolt 2001). Inversely, co-agonists are ambiently present and suggested to remain 
unsaturated at synaptic NMDA receptors receptors (Bergeron et al., 1998; Billups and Li 
et al., 2009). Since simultaneous agonist binding to all four subunits in the NMDA 
receptor is required for activation, phasic glutamate activation of NMDA receptors is 
akin to switching a speaker on/off, whereas tonic glycine or D-serine is analogous to the 
volume button.  
 Due to glutamate’s role in turning NMDA receptors on/off, its concentration is 
tightly controlled. Recent efforts have targeted co-agonist modulation in hopes to fine-
tune NMDA receptor responses. Glycine regulation has proven difficult due to various 
off-target effects and unsuccessful clinical outcomes (Cioffi 2018). This may be 
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attributed to glycine’s involvement in both sides of the excitatory and inhibitory balance. 
Glycine drives inhibitory tone through activation of inhibitory glycine receptors, while 
simultaneously increasing excitatory drive via its role as a co-agonist for excitatory 
NMDA receptors. Additionally, glycine modulates NMDA auto-receptor activation, 
internalization of NMDA receptors, and serine racemase activity (Zhang et al., 2008; 
Musante et al., 2011; Nong et al., 2003; Dunlop and Neidle, 2005; Marchetti et al., 
2013). As such, D-serine modulation has become a popular research focus.  
D-serine is synthesized from L-serine by serine racemase (SR) (Wolosker et al. 
1999a), and ambient levels are regulated by two families of neutral amino acid 
transporters: the sodium-independent alanine-serine-cysteine transporters (asc-1) and 
the sodium-dependent alanine-serine-cysteine transporters (ASCT1 and ASCT2) 
(Fukasawa et al., 2000; Nakauchi et al., 2000). The current model suggests that asc-1 
mediates efflux of D-serine from neurons, while the ASCTs facilitate influx of D-serine 
into astrocytes (Rosenberg et al., 2013; Wolosker et al., 2016; Foster et al., 2016). 
These properties are supported by studies employing use of small molecule inhibitors, 
where inhibiting asc-1 impairs LTP (Sason et al., 2017). Recently, Papouin and 
colleagues (2012) postulated D-serine as the principal synaptic co-agonist, and 
inversely, glycine as the preferential co-agonist at extra-synaptic NMDA receptors. This 
relationship favors targeting D-serine levels to treat neurological disorders involving 
synaptic NMDA receptor dysregulation. 
1.3 NMDA receptor subunit expression 
1.3.1 GluN1 splice variants 
GluN1 expression begins as early as embryonic day 14 and sustains extensive 
expression throughout life (Monyer et al., 1992). GluN1 is encoded by a single gene, 
GRIN1, with eight distinct isoforms (GluN1-1a to GluN14a and GluN1-1b to GluN1-4b), 
resulting from alternative splicing of three different exons (exon 5, 21, and 22) 
(Dingledine et al., 1999). Exon 5 is in the ATD and is present in GluN1-a and absent in 
GluN1-b isoforms, while the remaining alternatively spliced exons (21 and 22) are 
located in the CTD. GluN1 isoforms contain both CTD exons, GluN1-2 lacks exon 21, 
GluN1-3 lacks exon 22, and GluN1-4 lacks both CTD exons (Figure 1.3). 
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NMDA receptors containing GluN1-b isoforms have decreased agonist potencies 
and shorter durations of channel opening (Traynelis et al., 1995; Rumbaugh et al., 
2000; Vance et al., 2012; Yi et al., 2018). Similarly, ifenprodil, zinc, and proton 
sensitivity are also reduced in GluN1-b/GluN2B containing NMDA receptors (Figure 
1.3C). These pharmacological differences are postulated to arise from interactions 
between ATD and ABD domain contacts among GluN1 and GluN2 subunits (Reagan et 
P4 P8 P21 Adult 
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Figure 1. 3 Expression and functional properties of GluN1 splice variants. A) 
Autoradiogram showing the temporal and spatial expression of GluN1 splice 
variants. Ac nucleus accumbens, Cb cerebellum, Cp caudate-putamen, Cx cortex, 
DG dentate gyrus, DP dorsal pons, Hi hippocampus, Ob olfactory bulb, Th thalamus, 
VPn ventro-posterial thalamic nuclei. Modified from Paupard et al. 1997. B) 
Polypeptide linear representation of the 8 GluN1 splice variants. Exon 5 is in the 
ATD and is present in GluN1-a and absent in GluN1-b isoforms, while the remaining 
alternatively spliced exons (21 and 22) are located in the CTD. GluN1 isoforms 
contain both CTD exons, GluN1-2 lacks exon 21, GluN1-3 lacks exon 22, and 
GluN1-4 lacks both CTD exons. Adapted from Hansen et al., 2018. C) Ifenprodil 
concentration-inhibition data acquired in Xenopus oocytes expressing relevant 
subunits. NMDA receptors containing GluN1-1b subunits (i.e. containing exon 5) 
show reduced potencies to infenprodil. Adapted from Hansen et al., 2018. 
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al., 2018). Alternative splicing in the CTD (exons 21 and 22) influences NMDA receptor 
trafficking (Scott et al., 2003) and binding to intracellular proteins, including calmodulin 
(Ehlers et al., 1996 ; Wenthold et al., 2003 for review).  
Once established shortly after birth, GluN1 isoform expression remains stable 
throughout life. GluN1-a isoforms are expressed universally in the CNS, while GluN1-b 
isoforms are restricted to the sensorimotor cortex and thalamus. Similarly, GluN1-2 
isoforms are widely expressed, whereas GluN1-1 and GluN1-4 expression is regionally 
restricted. GluN1-1 is prevalent in rostral areas (cortex, hippocampus, caudate) while 
GluN1-4 is localized to caudal regions (thalamus, cerebellum, colliculi). GluN1-3 
expression is the lowest, with levels hardly detected in the cortex and hippocampus 
(Ewald and Cline, 2009  for review). 
1.3.2 GluN2 subunits 
GluN2 subunit expression largely dictates NMDA receptor functional 
heterogeneity. Temporal and spatial expression of GluN2 subunits is tightly regulated 
and gives rise to the fine-tuning of NMDA receptor responses throughout the brain. As 
seen in Figure 1.4, GuN2B and GluN2D are temporally intertwined as they are both 
expressed embryonically and dissipate into adulthood. Contrary, GluN2A and GluN2C 
aren’t present in the embryo, but rather become more prevalent as the organism 
matures (Monyer et al., 1994). 
 
P1 
P3 
P7 
P11 
P14 
P21 
Adult 
GluN1 GluN2A GluN2B GluN2C GluN2D GluN1/2A GluN1/2B GluN1/2C 
GluN1/2D 

decay
 ~50 ms 
decay
 ~400 ms 
decay
 ~290 ms 

decay
 >1 s 
A B 
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 In the mature brain, subunit expression is similarly parsed out for distinct 
functional profiling. GluN2A is primarily expressed in the neocortex and cerebellum, 
GluN2B is confined to the forebrain, GluN2C is found primarily in the cerebellum, and 
GluN2D is restricted to the diencephalon and mesencephalon. Within the hippocampus, 
subunit specificity extends into neuronal cell types. GluN2A and GluN2B subunits are 
found in CA1 and CA3 pyramidal cells, whereas GluN2C and GluN2D are restricted to 
different subsets of interneurons (Monyer et al., 1994). 
The properties discussed thus far regard diheteromeric NMDA receptors that contain 
GluN1 and one type of GluN2 subunit (e.g. GluN1/2A), though most neurons express at 
least two different GluN2 subunits. In fact, within the hippocampus and cortex, it has 
been estimated that the majority of NMDA receptors in pyramidal cells are 
triheteromeric GluN1/GluN2A/GluN2B receptors (Al-Hallaq et al., 2007; Luo 
et al., 1997; Rauner and Kohr, 2011; Sheng et al., 1994; Tovar et al., 2013; Review - 
Chazot and Stephenson, 1997). Our understanding of the structural and functional 
properties of triheteromers is limited due to difficulties in reliably expressing 
triheteromers, but a recent advance in triheteromer cell surface expression has 
expanded the scope of research abilities and lends promise to the further elucidation of 
these complex assemblies (Hansen et al., 2014). Due to this novel method, other 
triheteromeric complexes have been studied in more detail, including 
GluN1/GluN2A/GluN2C and GluN1/GluN2B/GluN2D. While NMDA receptors containing 
GluN1/GluN2A/GluN2C and GluN1/GluN2B/GluN2D exhibit intermediate properties 
seen in diheteromers (Hansen manuscript in preparation), GluN1/GluN2A/GluN2B 
triheteromeric assemblies are instead dominated by GluN2A associated properties (Sun 
et al., 2017). Therefore, GluN1/GluN2A and GluN1/GluN2A/GluN2B exhibit similar 
properties in terms of open probability and deactivation kinetics. This property bolsters 
Figure 1.4:  Expression and functional properties of GluN2A subunits. A) 
Autroradiogram showing the temporal and spatial expression patterns of GluN2 
subunits. Modified from Akazawa et al., 1994). B) Whole cell patch-clamp recordings 
of responses from synaptic-like application of 1mM glutamtate in diheteromeric 
NMDA receptors. The open tip current defines the extent of glutamate exposure, 
which was approximately 1ms. Adapted from Vicini et al., 1998) 
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the reliance of the developmental switch to GluN2A dominated synaptic NMDA 
receptors. 
1.4 NMDA receptors in brain function and disease 
NMDA receptors facilitate neuronal communication by correlating time-dependent 
activity between neurons. Communication among neurons is necessary for survival and 
successful signal integration can result in new connections, maintenance of current 
contacts, and weakening of others. Due its pivotal role in shaping synaptic contacts, 
NMDA receptors regulate development and maintenance of the nervous system.  
In neurodevelopment, NMDA receptor subunit expression is modulated to 
coordinate synapse formation and maturation. As synapses converge and establish 
communications, postsynaptic GluN2B-containing NMDA receptors act to promote 
synaptic stability and neuron survival. As neocortical development proceeds, GluN2A 
subunit expression commences and triggers synaptic refinement (Monyer et al., 1994; 
Sheng et al., 1994), a necessary process of maturation. Aberrant subunit expression or 
regulation has deleterious effects on proper neurodevelopment and maintenance, 
primarily regarding deficits in network formation and refinement. These deficits are 
postulated drive the pathophysiology of neurological disorders ranging from intellectual 
disability to epilepsy. 
Similarly, NMDA receptor modulation dictates synaptic plasticity throughout life. 
Alterations in NMDA receptor signaling can have adverse outcomes no matter the stage 
in life, whether it contributes to neurodevelopmental disorders or propagation of age-
related dementias. Age-related dementias like Alzheimer’s disease don’t necessarily 
involve mutated or malfunctioning NMDA receptors, but rather lose proper regulation of 
NMDA receptor activity. This can result from hyper- or hypoactivation of NMDA 
receptors, which may be caused by dysregulation of agonist/co-agonist levels 
(Peyrovian et al., 2019). 
Aberrant NMDA receptor signaling can result in the uncoupling of associated 
plasticity, unregulated feedback loops, and ultimately cell death. For example, chronic 
activation of extrasynaptic NMDA receptors leads to a diffuse Ca2+ influx and activation 
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of signaling cascades that favor cell death and LTD (Zhang et al., 2007; Leveille et al., 
2008; Ivanov et al., 2006). The idea that synaptic activation of NMDA receptors 
promotes cell survival and synaptic strengthening, whereas extrasynaptic activation 
promotes cell death and synaptic weakening is explored through the lens of various 
neurological disorders below.  
1.4.1 Ischemia  
During episodes of ischemia, glutamate transport is reversed, and instead of 
clearing excess glutamate, the glial EAAT2 transporter redirects transport and begins to 
release glutamate (Danbolt 2001). Excessive glutamate concentrations extensively 
activate NMDA receptors, and other iGluRs, which results in acute excitotoxicity. The 
NMDA receptor’s role in ischemia induced excitotoxicity is delineated by the fact that 
NMDA receptor antagonists are neuroprotective both in vitro and in vivo following an 
ischemic insult (Simon et al.,1984; Chen et al.,1991, 2008; Liu et al., 2007). 
Furthermore, NMDA receptor subunits contribute differently to the propagation of 
excitotoxicity, with GluN2B-selective antagonists alleviating excitotoxicity, while GluN2A 
antagonists exacerbate excitotoxicity-mediated neuronal cell death (Liu et al., 2007; 
Chen et al., 2008). A GluN2B-selective antagonist has shown clinical efficacy in 
reducing infarct volume if given two hours after stroke onset (Yang et al., 2003), 
whereas non-selective NMDA receptor antagonists need to be administered before 
stroke onset to protect against ischemic cell death (Liu et al., 2007; Margaill et al., 1996; 
Chen et al., 2008). Furthermore, decoupling of GluN2B scaffolding proteins, including 
PSD-95 and death-associated protein kinase-1, has been shown to protect neurons 
against ischemic insults (Aarts et al., 2002; Tu et al., 2010). 
1.4.2 Alzheimer’s disease 
In Alzheimer’s disease, amyloid-β peptides have been found to increase 
intracellular Ca2+ accumulation via activation of extrasynaptic-containing GluN2B 
receptors (Ferreira et al., 2012). Ablation of GluN1 and GluN2B extracellular terminals, 
but not of GluN2A, in cortical cultures prevented binding of amyloid-β oligomers to 
NMDA receptors (Costa et al., 2012). Furthermore, extrasynaptic activation of NMDA 
receptors led to an increase in amyloid-β secretion in cortical cultures (Bordji et al., 
2010). GluN2B antagonists were also able to rescue impairments in LTP (Rönicke et al., 
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2011; Li et al., 2011), amyloid-β facilitation of LTD (Li et al., 2009), and synaptic loss 
(Rönicke et al., 2011; Liu et al., 2010). Similar to ischemic insults, a decoupling of 
GluN2B with PSD-95 was able to prevent amyloid-B induced toxicity, including memory 
deficits and improved survival in a mouse model of Alzheimer’s disease (Ittner et al., 
2010).  
1.4.3 Depression 
The etiology of depression is highly heterogeneous and can result from a 
multitude of both genetic and environmental factors including monoamine deficiencies, 
impaired circadian rhythms, aberrant hypothalamic-pituitary-axis activity, reduced 
GABA-ergic activity, and NMDA receptor dysfunction (Review - Hasler 2010). Despite 
this diverse pathological profile, the monoamine hypothesis of depression has 
dominated clinical treatment strategies (Mann 2005). However, serotonin-reuptake-
inhibitors and similar monoamine targeting treatments have a delayed onset of action 
and limited efficacy in treating depression. This lends to the hypothesis that the 
monoamine system is a downstream consequence of a separate upstream abnormality. 
The glutamate hypothesis of depression is supported by use of NMDA receptor 
antagonists and glutamate release inhibitors (Kendell et al., 2005). Administration of 
ketamine to patients with treatment-resistant major depressive-disorder produced rapid 
and substantial antidepressant effects (Zarate et al., 2006). Ketamine is thought to 
counteract depression via inhibition of NMDA receptor-mediated spontaneous activity of 
GABAergic inhibitory interneurons, fortifying the hypothesis that depression results from 
an increase in inhibitory drive (Homayoun and Moghaddam, 2007). A GluN2B 
antagonist, Ro 25-6981, showed similar results to ketamine in both mechanism of 
action, onset, and longevity (Li et al., 2011). Due to the success seen with NMDA 
receptor antagonists, the FDA has recently approved a ketamine-laced nasal spray for 
treatment-resistant depression (2019). 
1.4.4 Epilepsy 
Epilepsy is a result of hypersynchronous electrical discharges that result in 
overactivation of the excitatory system. Ketamine has shown success in neuroprotection 
and reducing neuroinflammation when administered during status epilepticus (i.e. a 
seizure lasting more than five minutes) (Dorandeu et al., 2013). Similarly, MK-801 (an 
 15 
NMDA receptor antagonist) administration after 90 minutes of status epilepticus was 
shown to be neuroprotective, but like ketamine, failed to prevent future seizures (Brandt 
et al., 2003). A GluN2B antagonist, ifenprodil, has also shown to mirror the 
neuroprotective action of broad-spectrum NMDA antagonists, like MK-801, in epilepsy 
models. Additionally, GluN2B extrasyanptic expression increases, while synaptic 
expression decreases following an epileptic event (Frasca et al., 2011). This suggests 
that epileptogenesis is not solely mediated by NMDA receptors, albeit NMDA receptor 
hyperactivation is a contributor to neuronal cell death during seizures. However, there 
has been some success with memantine mediated epileptiform reduction in a patient 
with a GluN2A gain-of-function mutation, although memantine was unable to rescue the 
associated cognitive deficits (Pierson et al., 2014). 
1.4.5 Schizophrenia 
Similar to depression, schizophrenia has traditionally been considered a 
monoamine disorder. While targeting the dopaminergic system alleviates the positive 
symptoms (i.e. hallucinations) associated with schizophrenia, hyperactive dopaminergic 
signaling does not explain the negative or cognitive deficits. (Moghaddam and Javitt, 
2012; Lewis, 2012). Again, as with depression, this suggests that monoamines play a 
downstream role and once again the glutamate hypothesis is implicated in disease 
etiology. However, unlike depression, schizophrenia is thought to result from 
hypofunctioning NMDA receptors located in interneurons (Moghaddam and Javitt, 
2012). 
 
Evidence fortifying the NMDA receptor hypofunction hypothesis includes: 1) 
NMDA receptor antagonists can reproduce schizophrenia-like symptoms in healthy 
humans (Coyle, 2006). 2) Reduced NMDA receptor expression (specifically GluN2A 
subunits) is seen in parvalbumin interneurons in post-mortem samples from individuals 
with schizophrenia (Belforte et al., 2010). 3) Depletion of D-serine, a selective co-
agonist at NMDA receptors, can cause schizophrenia-like behaviors in mice (Labrie et 
al., 2009), and reduced levels of D-serine have been reported in the cerebrospinal fluid 
and blood of schizophrenic patients (Hashimoto et al., 2003). 4) D-serine administration 
can rescue schizophrenia induction by PCP, an NMDA receptor antagonist similar to 
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ketamine (Anderson et al., 2004). These data implicate that enhancing NMDA receptor 
activity could ameliorate deficits in inhibitory drive seen in patients with schizophrenia. 
1.5 De novo GRIN mutations 
De novo mutations are spontaneously occurring, i.e. they are not inherited across 
generations. There are fewer single nucleotide polymorphisms, aka de novo mutations, 
in GRIN genes than to be expected, indicating that GRIN genes are highly intolerant to 
variation (Petrovski et al., 2013). Recently, XiangWei and colleagues (2018) assessed 
258 GRIN variants which are not present in the healthy human population (gnomAD 
database assessed August 2, 2017). Of these 258 single nucleotide polymorphisms, 
10% resided in GluN1, 39% in GluN2A, 45% in GluN2B, 3% in GluN2C, and 3% in 
GluN2D. Additionally, 65% of these mutations were found to be missense, 9% 
nonsense, 9% frameshift, 5% splice site, and 12% were uncategorized. 
Mutations in single subunits are often comorbid with neuropsychiatric disorders. 
For example, 77% of patients with an NMDA receptor mutation present with intellectual 
disability, 49% with epilepsy, 19% with autism spectrum disorder, 5% with 
schizophrenia, and 2% with attention deficit hyperactivity disorder.  The most prevalent 
behavioral outcome associated with mutations in GluN1, GluN2B or GluN2C was 
intellectual disability, while epilepsy was highly correlated with mutations in GluN2A, 
and GluN2D mutations were associated with schizophrenia. 
As GluN1 is expressed universally in both temporal and spatial respects, It is 
unsurprising that mutations are more likely to result in intellectual disability with or 
without comorbid epileptiform activity. On the molecular and cellular level, intellectual 
disability can manifest as the inaccurate encoding of information between and among 
neurons. Similarly, GluN2B shares a similar phenotypic outcome in regard to 
prevalence of intellectual disability due to its prevalence in synapse formation and 
stabilization during development. GluN2A on the other hand is highly associated with 
epilepsy, with 78% of patients presenting with symptoms falling under the epilepsy-
aphasia spectrum disorder phenotype (XiangWei et al., 2018).  
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1.5.1 Epilepsy-aphasia spectrum disorders 
The epilepsy-aphasia spectrum (EAS) is a broadly defined category of abnormal 
CNS electrical activity coupled with language loss and in severe cases, intellectual 
disability. Language impairments can include deficits in reading, writing, and speaking 
and appear in early childhood. In severe cases, children develop EAS months after 
birth, while children with more moderate EAS begin showing symptoms around five 
years of age.  
 Epileptiform profiles of EAS include Landau-Kleffner syndrome, epileptic 
encephalopathy with continuous spike-and-wave during sleep syndrome, and various 
forms of benign childhood epilepsy with centrotemporal spikes. Both Landau-Kleffner 
syndrome and epileptic encephalopathy with continuous spike-and-wave during sleep 
syndrome show abnormal epileptiform activity (i.e. spike-and-wave discharges) during 
more than 85% of slow-wave sleep, whereas abnormal EEG activity seen in benign 
childhood epilepsy with centrotemporal spikes occurs in less than 85% of slow-wave 
sleep. These three main classifications of epileptiform activity seen in EAS all share the 
same attribute of manifesting during sleep and largely remitting upon awakening. 
Benign childhood epilepsy with centrotemporal spikes is the most prevalent childhood 
epilepsy and generally presents with mild language loss (Bradley et al., 1990). Seizures 
occur in the rolandic area of the brain and generally subside at the end of adolescence, 
hence its benign classification. Conversely, Landau-Kleffner syndrome and epileptic 
encephalopathy with continuous spike-and-wave during sleep syndrome are more 
severe forms of EAS, and in some cases, present earlier and do not subside upon 
adulthood. Individuals with epileptic encephalopathy with continuous spike-and-wave 
during sleep syndrome show nearly continuous (≥85%) high amplitude bilateral slow 
spike wave activity during non-rapid eye movement sleep. Children with Landau-
Kleffner syndrome show similar EEG patterns, but don’t develop language loss until 
around five years of age (Carvill et al., 2013). 
The etiology of EAS is still being uncovered, though recently whole exome 
genome sequencing lead by the National Institute of Health (NIH) Undiagnosed 
Diseases Program (UDP) elucidated the role of GRIN2A mutations in EAS. Mutations in 
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GluN2A subunits are more prevalent in severe forms of EAS, accounting for up to 20% 
of children with Landau-Kleffner syndrome and epileptic encephalopathy with 
continuous spike-and-wave during sleep syndrome, while only being implicated in about 
5% of children with benign childhood epilepsy with centrotemporal spikes. The current 
treatment strategies include general anticonvulsants and corticosteroids, albeit these do 
not ameliorate cognitive deficits associated with EAS. 
1.6 Possible strategies for NMDA receptor modulation in disease 
 Dysfunctional NMDA receptors underlie various forms of neurological disorders 
and accordingly, serve as an attractive therapeutic target for clinical intervention. While 
many NMDA receptor modulators have been approved for clinical trials, few have 
shown significant improvement of NMDA receptor-mediated neurological disorders. One 
pharmaceutical, memantine, has shown clinical success in treating moderate-to-severe 
Alzheimer’s disease and has been approved by the Food and Drug Administration 
(FDA). Memantine is a non-selective open channel blocker, which is just one flavor of 
modulation possible for NMDA receptors. NMDA receptors can also be modulated by 
more indirect means, including NMDA receptor trafficking. 
1.6.1 Modulating NMDA receptor trafficking 
 Synaptic activity and efficacy can be regulated by NMDA receptor trafficking to 
and within the plasma membrane (Barria et al., 2002). Within hours after synaptic 
activity, NMDA receptor trafficking is initiated to and from synapses (Quinlan et al., 
1999), and synaptic retention and release is dependent on future synaptic activity (Rao 
et al., 1997). NMDA receptor trafficking is targeted via the CTD and different subunits 
have altered proclivities to endo- and exocytosis (for review see Perez-Otano and 
Ehlers 2005). For example, alternative splicing of the GluN1 CTD to include the C2 
cassette (GluNR1-3a and 3b) facilitates trafficking to the membrane (Scott et al., 2001; 
Okabe et al., 1999). Additionally, phosphorylation by protein kinase C promotes dual 
properties of NMDA receptor regulation by both promoting translocation from synaptic to 
extrasynaptic sites (Fong et al., 2002) and exocytosis of NMDA receptors from the 
endoplasmic reticulum (Scott et al., 2003; Lan et al., 2001). Finally, GluN2A and 
GluN2B differ in their affinity for internalization, where GluN2B is more readily 
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internalized due to amino acid motifs in the CTD which attract internalization machinery 
more effectively than GluN2A subunits (Lavezzari et al., 2004).  
 Inhibition of protein kinase C mediated exocytosis can be inhibited by a dominant 
negative mutant of soluble NSF-associated protein and botulinum neurotoxin A (Lan et 
al., 2001). Similarly, blocking GluN2B associations with PSD-95 to promote lateral 
mobility to extrasynaptic sites has been experimentally utilized in Alzheimer’s disease 
(Ittner et al., 2010) and neuroprotection in stroke (Aarts et al., 2002). Therefore, 
targeting NMDA receptor trafficking could prove to be a valuable therapeutic strategy to 
modulate NMDA receptor activity.  
1.6.2 Modulation of co-agonist occupancy 
Functional evidence has indicated that D-serine is the principal coagonist at 
mature excitatory synapses in the hippocampus (Mothet et al., 2000; Yang et al., 2003; 
Henneberger et al., 2010; Papouin et al., 2012), hypothalamus (Panatier et al., 2006), 
spinal cord (Wake et al., 2001), brainstem (Berger et al., 1998), retina (Stevens et al., 
2010) and prefrontal cortex (Fossat et al., 2012). The degree of saturation in these 
regions vary and this poses the possibility that regulation of glycine/D-serine levels may 
prove to be an effective therapeutic target for NMDAR hypo- and hyperfunction 
disorders. However, since manipulation of glycine has off target effects, like activation of 
glycine receptors (Zhang et al., 2007), interaction with NMDA autoreceptors (Musante et 
al., 2011), internalization of NMDAR (Nong et al., 2003) and modulation of serine 
racemase (Dunlop and Neidle, 2005; Marchetti et al., 2013), controlling D-serine levels 
has become a popular research focus.  
D-serine was shown to be significantly present in the brain by Hashimoto and 
colleagues in 1992. This was a monumental discovery because, canonically, D-amino 
acids were not thought to be present in significant concentrations in eukaryotes. After 
this revolutionary discovery, the functional importance of D-serine in regulating 
physiological processes like neural migration and proliferation (Kim et al., 2005; Huang 
et al., 2012), synaptic plasticity (Mothet et al., 2000; Yang et al., 2003; Panatier et al., 
2006; Henneberger et al., 2010; Papuan et al., 2012; Li et al., 2013; Rosenberg et al., 
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2013), and neurotoxicity (Mustafa et al., 2010; Watanabe et al., 2016) has started to 
emerge. 
D-serine is synthesized by the pyridoxal-5’-phosphate-dependent serine 
racemase (SR) (Wolosker et al. 1999a, b,), degraded by the peroxysomal flavoprotein 
D-amino acid oxidase (DAAO) (Krebs 1935; Mothet et al., 2000; review see Pollegioni 
and Sacchi 2010), and transported across membranes by astrocytic vesicular release 
(Mothet et al., 2005; Henneberger et al., 2010) and two known families of neutral amino 
acid antiporters. The Alanine-Serine-Cysteine Transporter (ASCT; SLC1A5 and 
SLC1A5) belongs to the Solute Carrier family (SLC) of membrane transporters, and in 
accordance with the glutamate transporters, is sodium-dependent with a 
thermodynamically uncoupled chloride conductance (Zerangue and Kavanaugh, 1996). 
Alternatively, the alanine-serine-cysteine transporter-1 (asc-1; SLC7A10) binds with a 
single membrane spanning type II membrane glycoprotein (4F2), and is sodium-
independent with no associated conductance (Fukasawa et al., 2000).  
Early studies indicated that ASCTs transport D-serine with low affinity, and thus 
asc-1 has been the primary research focus for D-serine transport. Asc-1 is localized to 
neurons (Helboe et al., 2003) and has a high affinity for D-serine and glycine (Fukasawa 
et al., 2000; Nakauchi et al., 2000; Matsuo et al., 2000; Rosenberg et al., 2013). 
However, the neuronal supply of D-serine by asc-1 can’t account for all of the D-serine 
that is released and available for NMDAR binding (Yang et al., 2003; Rutter et al., 
2007). We have recently shown that ASCTs also transport D-serine, with micromolar 
potency (Foster et al., 2016). The current model, termed the D-serine shuttle 
hypothesis, supports that asc-1 is responsible for the efflux and ASCT1/2 for the influx 
of ambient D-serine (Wolosker et al., 2016). This indicates that therapeutic targets for 
these neutral amino acid transporters could ameliorate hyper- or hypoactive NMDA 
receptor disorders. 
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1.6.3 NMDA receptor ligands  
1.6.3.1 – Orthosteric antagonists  
 Orthosteric antagonists bind in the agonist binding pocket and have been 
instrumental in elucidating NMDA receptor’s role in physiological processes. In 1983, a 
seminal paper by Collingridge and colleagues showed that an NMDA receptor 
antagonist, 2-amino-5-phosphonopentanoate (AP5), was able to prevent induction of 
LTP at high frequency stimulation, with minimal modification at low frequency 
stimulations (Collingridge et al., 1983). This paper introduced the importance of NMDA 
receptors in LTP induction, a finding that had little support before use of AP5 (for review 
see Lodge et al., 2018). Additionally, determination of the two-site model (i.e. two 
glutamate and two glycine are required for NMDA receptor activity) was elucidated by 
use of glutamate and glycine competitive antagonists, AP5 and 7-chlorokynurenic acid 
(7CK), respectively (Benveniste and Mayer, 1991). 
 Despite the utility of competitive antagonists in illuminating the importance and 
basic properties of NMDA receptors, discovery of GluN2 subunit-selective antagonists 
has been a multi-decade long hurdle for the field. This is attributed to the conservation 
of amino acid motifs surrounding the glutamate binding pocket in GluN2 subunits 
(GluN2 binds glutamate, GluN1 binds glycine). However, recent progress in selectivity 
has surfaced with compounds that extend deeper into the pocket, in the space between 
ABDs (Lind et al., 2017).  
1.6.3.2 Allosteric antagonists 
 Allosteric antagonists are defined as ligands that bind anywhere outside the 
active site (i.e. orthosteric site) and selective allosteric antagonists exist for all GluN2 
subunits. There are various flavors of allosteric antagonism including ion channel 
occlusion, desensitization state stabilizers, and negative modulation of agonist binding. 
Here we will discuss memantine (a non-selective antagonist), ifenprodil (GluN2B 
selective antagonist), and TCN-201 (a GluN2A selective antagonist). 
 Memantine, a positively charged compound at physiological pH, is considered 
an uncompetitive open channel blocker at all NMDA receptor types. Memantine can be 
thought of as use-dependent because it can only bind to open, active, NMDA receptors. 
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Within the open channel blocker umbrella, there are three main delineations – 1) foot in 
the door blockers prevent channel closure; 2) partial trapping blockers (memantine) 
impede channel closure but are unable to completely prevent it; 3) trapping blockers 
(ketamine) allow channel closure and agonist unbinding while being trapped in the 
channel pore. While considered non-selective, memantine and ketamine show a 5-10 
fold preference for GluN2C/D containing NMDA receptors (Kotermanski and Johnson, 
2009). Memantine is approved by the FDA to treat mild to severe Alzheimer’s disease 
and is well tolerated, possibly due to its relatively fast blocking/unblocking kinetics which 
would result in reduced channel block during normal synaptic transmission (Chen and 
Lipton, 2006). 
Ifenprodil, a GluN2B selective antagonist, binds in the ATD dimer interface (i.e. 
between GluN1 ATD and GluN2B ATD) (Karakas et al., 2009) and is hypothesized to 
inhibit NMDA receptor activity by both stabilizing a desensitized state (Zhu et al., 2016) 
and enhancing proton-mediated inhibition of NMDA receptor activity (Traynelis et al., 
1995; Pahk and Williams 1997)). Ifenprodil has been instrumental in illustrating GluN2B-
contaning NMDA receptor involvement in various physiological processes and was used 
in a small clinical trial as an adjunct with L-DOPA to improve symptoms in Parkinson’s 
patients, although no significant difference was found (Montastruc et al., 1992). 
 
TCN-201, a GluN2A selective antagonist, binds in the ABD dimer interface (i.e. 
between GluN1 ABD and GluN2A ABD) and acts to destabilize glycine binding (Yi et al., 
2016). Given this relationship, TCN-201 negatively modulates glycine binding and 
glycine negatively modulates TCN-201 binding (Hansen et al., 2012). The MPX 
compounds (Volkmann et al., 2016), a next-generation class of selective GluN2A 
negative allosteric modulators (NAMs), have been characterized and show decreased 
sensitivity to glycine and ability to inhibit GluN1/GluN2A/GluNB triheteromers, unlike 
ifenprodil (Hansen et al., 2014).  
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2.0 Characterization of NAM-mediated inhibition of NMDA receptors harboring GluN2A 
gain-of-function mutations 
2.1 Introduction 
    Glutamatergic synapses dictate the majority of excitatory neurotransmission in the 
central nervous system and as such are intimately involved in physiological processes 
ranging from neuronal survival to neurodevelopment and synaptic re-modeling. Within 
the ionotropic glutamate receptor family, NMDA receptors act as coincidence detectors 
to summate excitatory neurotransmission noise into binary all-or nothing signal 
propagation. NMDA receptors require membrane depolarization to relieve a tonic Mg2+ 
block and binding of both agonist and co-agonist at all four subunits in order to activate 
a non-selective mono- and divalent cation channel that’s permeable to calcium 
(Traynelis et al., 2010). In doing so, NMDA receptors translate chemical messages into 
calcium influx to activate second messenger cascades that dictate the aforementioned 
physiological processes.  
    During cortical neurodevelopment, postsynaptic NMDA receptors predominantly 
express GluN1/GluN2B diheteromers (Monyer et al., 1994; Sheng et al., 1994), which 
serve to initiate synaptic contacts among migrating and newly born neurons. As 
development proceeds, GluN2A subunit expression commences and subunits are 
subsequently trafficked to the membrane to join GluN1 and GluN2B-containing NMDA 
receptors at postsynaptic densities (Tovar and Westbrook, 1999). Increasing prevalence 
of GluN2A subunits confers synaptic refinement and general network maturation 
(McKay et al., 2018), possibly by governing the dynamics of the excitatory postsynaptic 
current.  
This concept of GluN2B subunit dominance in synaptogenesis and GluN2A 
subunit in synaptic refinement is bolstered by the finding that GluN2B knockout mice die 
upon birth (postnatal day 0) (Kutsuwada et al., 1996), whereas GluN2A knockout mice 
are viable and fertile into adulthood (Sakimura et al., 1995). Further, mutations in 
GluN2B predominately manifest with intellectual disability (87% 101/116 patients) while 
mutations in GluN2A present with both epilepsy (78% 78/100 patients) and intellectual 
disability (70%) (XiangWei et al., 2017). 
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Recently, due to advances in next-generation whole exome sequencing, the 
gene encoding GluN2A (GRIN2A) has been implicated in the etiology of early-onset 
epilepsy-aphasia spectrum (EAS) disorders including benign childhood epilepsy with 
centrotemporal spikes, Landau-Kleffner syndrome, and epileptic encephalopathy with 
continuous spike-and-wave during sleep syndrome. Benign childhood epilepsy with 
centrotemporal spikes is the most prevalent (15-20%) focal epilepsy seen in children, 
with an age of onset between 1-14 years (Watanabe et al., 2004) and characterized by 
infrequent focal facial sensorimotor seizures during sleep with high-voltage focal spikes 
in rolandic regions (i.e. the motor cortex). Approximately 50% of children with benign 
epilepsy with centrotemporal spikes show seizure evolution to generalized tonic-clonic 
seizures (bilateral synchronous sharp waves or sharp and slow wave complexes). 
However, this seizure classification is considered benign because seizures remit in 
adolescence with minimal alterations in language understanding and output. 
Landau-Kleffner syndrome is considerably less prevalent with an occurrence of 
about one in a million and general age of onset between 5-14 years. Similar to benign 
childhood epilepsy with centrotemporal spikes, Landau-Kleffner syndrome can show 
benign EEG patterns (i.e. focal epileptiform discharges) that transgress to aberrant 
epileptiform events in nearly half of children with Landau-Kleffner syndrome. 
Additionally, bilateral epileptiform discharges in the perisylvian cortex (cortex 
surrounding the lateral sulcus – implicated in speech understanding and output) have 
been documented in children with Landau-Kleffner syndrome (Paetau 2009). Children 
with Landau-Kleffner syndrome live limited lives due to the resultant language and 
overall cognitive difficulties and have poor prognoses. 
Like Landau-Kleffner syndrome, the age of onset for epileptic encephalopathy 
with continuous spike-and-wave during sleep syndrome is about 5 years old with 
disease progressing into multifocal epileptiform discharges or bilaterally synchronous 
spike and wave discharges that can last for more than 30 minutes. Seizures become 
more frequent as the child ages and by about 1-2 years after onset, patients can 
develop epileptic encephalopathy with status epilepticus during slow-wave sleep. 
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Epileptiform activity dominates 85% of slow wave sleep and results in severe cognitive 
deficits like those seen in Landau-Kleffner syndrome (Review - Lee et al., 2017). 
In this work, we have selected six representative de novo (i.e. spontaneously 
occurring, not inherited) GRIN2A mutations seen in children with EAS. We have 
focused our studies on NMDA receptors containing GluN2A gain-of-function mutations, 
though both loss and gain-of-function GRIN2A mutations have been implicated as the 
monogenic cause in up to 20% of patients with severe EAS (i.e. Landau-Kleffner and 
epileptic encephalopathy with continuous spike-and-wave during sleep syndromes). 
These representative mutations are located throughout the agonist binding domains 
(ABDs), linker regions between the ABD and transmembrane domains (TMDs), and one 
at the apex of the M2 re-entrant loop of the TMD. 
A male pediatric patient (17 years old) presenting with rolandic focal epilepsy 
with centrotemporal spikes underwent whole-exome sequencing to reveal a GluN2A-
N447K mutation (Xu et al., 2018). His first seizure, generalized tonic-clonic, occurred at 
nine years old and then he developed nocturnal rolandic epilepsy (bilateral high-voltage 
spikes and spike and slow wave discharges in centrotemporal regions). Spike 
discharges occupied about 50% of slow wave sleep which falls under the criteria for 
rolandic epilepsy (a criteria of >80% is required to be classified as epileptic 
encephalopathy with continuous spike-and-wave during sleep syndrome). 
Diheteromeric NMDA receptors containing GluN2A-N447K mutation shows increased 
current density, increased glutamate potency, and a reduction in Mg2+ block (Xu et al., 
2018).  
A GluN2A-P552R mutation was detected in a female patient with severe 
intellectual disability and seizure disorders (Ogden et al., 2017; de Ligt et al., 2002). Age 
of seizure onset was 9 months and her development began slowing down at 3 months. 
Speech was not developed, and she had severely delayed psychomotor development. 
GluN2A-P552R is located in the pre-m1 linker region and NMDA receptors containing 
GluN2A-P552R subunits have increased agonist potencies, channel open time, 
deactivation kinetics, and sensitivity to Zn2+ inhibition (9nM vs 27nM in wild type 
GluN2A containing NMDA receptors) (Ogden et al., 2017). 
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A young female with a GluN2A-N615K mutation presented with epileptic spasms 
and myoclonic seizures starting at 3 months of age, along with behavioral anomalies, 
severe mental retardation, and muscular hypotonia (Endele et al., 2010). The GluN2A-
N615K mutation lies at the tip of the Mg2+ sensor in the M2 re-entrant loop and this 
lysine replacement causes polar displacement of Mg2+ which results in insensitivity to 
tonic Mg2+ block. This is considered gain-of-function because NMDA receptors 
containing GluN2A-N615K mutations are more easily activated and have thus converted 
from coincidence detectors to something more closely resembling calcium-permeable 
AMPA receptors. 
The GluN2A-K669N mutation, located in the ABD, was identified by a research 
group who extracted data from the ExAC Browser (includes 60,706 exomes from 
unrelated individuals) for missense variants in GluN2A and GluN2B subunits (Swanger 
et al., 2016). The patient with a GluN2A-K669N mutation presented with epilepsy, and 
NMDA receptors containing GluN2A-K669N subunits show increases in agonist 
potencies, decreased open probability (0.04 compared to 0.18 seen in wild type GluN2A 
containing NMDA receptors), and increased deactivation time course (Swanger et al., 
2016). 
Both GluN2A-L812M and M817V mutations are located in the pre-M4 linker 
region and the patients who harbor these mutations presented with early-onset epileptic 
encephalopathy and severe developmental delay. NMDA receptors containing GluN2A-
L812M or M817V show increased agonist potencies, prolonged deactivation time 
course, and increases in channel open time and probability (Yuan et al., 2014; Chen et 
al., 2017). However, while these mutations are in close proximity, NMDA receptors with 
GluN2A-L812M mutations are more sensitive to memantine (IC50 12µM) compared to 
receptors with GluN2A-M87V subunits (IC50 30µM), which indicates that mutation 
location does not predict drug interactions.  
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Treatment strategies for children with EAS disorders generally include valproate 
along with voltage-gated sodium channel blocker prescriptions, or in some cases, 
memantine. These broad spectrum central nervous system depressants are not without 
side effects, yet despite best efforts it has been difficult to find >10-fold selective 
antagonists for GluN2A. Recently, GluN2A selective modulators were identified in a 
Glaxo-Smith-Kline high-throughput screen campaign. It was found that these 
compounds act as negative allosteric modulators (NAMs) of glycine binding to the 
GluN1 subunit (TCN-201; Hansen et al., 2012) and, as with GluN2A positive allosteric 
modulators, bind at the dimer interface between GluN1 and GluN2A subunits (Yi et al., 
2016; Hackos et al., 2016). More recent analogs (MPX-004 and MPX-007) have been 
identified that are less sensitive to glycine than TCN-201 (Volkmann et al., 2016). These 
GluN2A NAMs are completely selective for NMDA receptors containing GluN2A 
subunits (Figure 2.1). 
 
Here we have evaluated NAM binding and degree of inhibition during both 
equilibrium and non-equilibrium states for NMDA receptors harboring wild type GluN2A 
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Figure 2.1: Chemical structure and pharmacology of GluN2A-selective NAMs. 
A) Chemical structures of GluN2A-selective negative allosteric modulators (NAMs). 
B) Concentration-inhibition data for GluN2A-selective NAMs at recombinant NMDA 
receptors. Adapted from Yi et al., 2016. Data are mean ± SEM from 4-11 oocytes 
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or GluN2A subunits with gain-of-function mutations. We found that while the NAMs can 
overcome increases in glycine potency seen in gain-of-function mutants, inhibition and 
agonist potency are different in steady-state vs synaptic-like activation of NMDA 
receptors. Furthermore, we have identified a gain-of-function mutant, GluN2A-P552R, 
which causes a conformational change in the dimer interface that impedes NAM 
binding.  
2.2 Methods  
2.2.1 RNA preparation and injection 
Rat cDNAs for GluN1-1a (GenBank accession number U08261; hereafter GluN1) 
and GluN2A (D13211) were provided by Drs. S. Heinemann and S. Nakanishi. For 
expression in Xenopus oocytes, DNA constructs were linearized by restriction enzymes 
and used as templates for in vitro cRNA transcription using the mMessage mMachine 
kit (Thermo Fisher Scientific). Oocytes were purchased from Xenopus 1 and the follicle 
layer was subsequently removed by treating the oocytes with 0.5 mg/ml collagenase 
(type IA; Sigma-Aldrich) in OR-2 buffer (in mM: 82.5 NaCl, 2.0 KCl, 1.0 MgCl2, and 5.0 
HEPES pH 7.6) at room temperature for 2-3 hours. cRNAs were combined at a ratio of 
1:2 for GluN1 and GluN2 and diluted with RNase-free water to achieve desired 
expression levels (i.e. recorded currents <10µA). Electrophysiological recordings were 
performed 2–4 days after cRNA injection at room temperature (23 °C) and were 
incubated at 17 °C (for 2-4 days) in modified Barth’s solution containing (in mM) 88 
NaCl, 2.4 NaHCO3, 1 KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 0.82 MgSO4, and 5 Tris⋅HCl (pH 
7.5 with NaOH) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin 
(Invitrogen) as well as 50 mg/mL gentamicin (Fisher Scientific).  
 
2.2.2 Two-electrode voltage clamp (TEVC) solutions and electrophysiology  
Recordings were performed 2–5 days after cRNA injection at room temperature 
(23°C) using a two-electrode voltage-clamp amplifier (OC725; Warner Instruments, 
Hamden, CT). The signal was low-pass filtered at 20 Hz (4-pole, -3 dB Bessel; 
Frequency Devices, Haverhill, MD) and digitized using PCI-6025E or USB-6212 BNC 
data acquisition boards (National Instruments, Austin, TX). Oocytes were placed in a 
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custom-made chamber and continuously perfused (approximately 5 ml/min) with oocyte 
recording solution containing (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl2, and 0.01 
EDTA (pH 7.4 with NaOH). DMSO was controlled for each experiment and recording 
electrodes were filled with 3 M KCl. Approximately 10-30 min before recordings, oocytes 
were injected with 20-50 nL of 50 mM BAPTA to prevent activity-dependent increases in 
response amplitude (Williams, 1994). Oocytes were voltage-clamped at -40 mV during 
recordings. Glutamate (L-glutamic acid) and glycine were purchased from Sigma-
Aldrich, TCN-201 from Hello Bio, and MPX compounds kindly supplied by Mnemosyne 
Pharmaceuticals. 
2.2.3 TEVC data analysis  
Concentration-response data were analyzed using GraphPad Prism (GraphPad 
Software v8). Data from individual oocytes were fitted to the Hill equation and fitted for 
EC50 vaules: 
I = Imax/(1 + 10^(logEC50 − log[A]) * nH))  
Where Imax is the maximum current in response to the agonist, nH is the Hill 
slope, [A] is the agonist concentration, and EC50 is the agonist concentration that 
produces half-maximum response.  
IC50 values: 
I = Imin + (Imax – Imin)/(1+10^((log[A]-logIC50)*nH)), where Imin is the minimum current in 
response to the agonist plus a saturating concentration of antagonist. Maximal inhibition 
was calculated as 1-(Imin/Imax). 
For graphing, data points were normalized to the maximum current response in 
the same recording and the averaged data were then fitted to the Hill equation and 
plotted together. For compounds evaluated using Schild analysis (Arunlakshana and 
Schild, 1959), the glycine EC50 was measured in the absence of antagonist (TCN-201) 
and EC50′ measured in the presence of increasing concentrations of TCN-201. These 
values were used to calculate a dose ratio (DR= EC50′/EC50) for each TCN-201 
concentration and log (DR - 1) was plotted versus TCN-201 concentration. The slope of 
the Schild plot is 1 for a competitive antagonist according to the Schild equation: log 
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(DR - 1) = pKi + log[B], where[B] is the antagonist concentration and pKi is the negative 
logarithm of the antagonist concentration that produces a two-fold shift of the agonist 
EC50 (i.e. Ki is the antagonist binding affinity).  
Response = 1/(1+ (EC50′/[A])nH), 
EC50′ = EC50(1 + [B]/KB)/(1+ α[B]/ KB), 
Where [A] is the agonist concentration, [B] is the antagonist concentration, EC50 
is for glycine in the absence of TCN-201, EC50′ is for glycine in the presence of different 
concentrations of TCN-201, nH is the Hill slope, and KB is the dissociation constant for 
TCN-201. All data are presented as mean ± SEM.  
2.2.4 HEK293 cell culture and transfection 
HEK-293 cells were cultured in Dulbecco’s Modified Eagle's Medium with 
GlutaMax-I (Invitrogen) supplemented with 10% dialyzed FBS, 1 mM sodium pyruvate, 
10 U/mL penicillin, and 10 µg/mL streptomycin and plated in 24-well plates on glass 
coverslips coated with 0.1 mg/mL poly-d-lysine ∼48 h before the experiments. For 
expression of GluN1/2A, cells were transfected with plasmid cDNAs encoding GluN1 
and GluN2 subunits at a ratio of 1:2. We used the calcium phosphate precipitation 
method as follows: to transfect four wells in a 24-well plate, 10 µl plasmid DNA (0.2 
µg/µl; total 2 µg DNA) was mixed with 65 µl H2O and 25 µl 1 M CaCl2. This DNA-CaCl2 
solution was then mixed with 100 µl 2 × BES solution composed of (in mM) 50 N,N-
bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 280 NaCl, 1.5 Na2HPO4 (pH 
6.95 with NaOH), incubated for 12-15 minutes, and 50 µl of this solution (of the 200 µl 
total) was then added dropwise to each of four 24-wells containing cells and 500 µl 
culture medium. To minimize cytotoxicity, the culture medium was replaced 4–6 h after 
transfection with medium containing NMDA receptor antagonists D,L-AP5 and 7-CKA 
(200 µM each). Experiments were performed ∼24 h after transfection. 
Whole-cell voltage-clamp recordings were performed using an Axopatch 200B 
amplifier (Molecular Devices) at room temperature (23°C) with the holding potential at 
−60 mV. Whole-cell currents were measured using pClamp10 (Molecular Devices) and 
low-pass filtered at 20 Hz (4-pole, -3 dB Bessel; Frequency Devices, Haverhill, MD) and 
digitized using PCI-6025E or USB-6212 BNC data acquisition boards (National 
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Instruments, Austin, TX). Series resistance was compensated 85-90% with the 
prediction and correction circuitry in all experiments.  Electrodes were filled with internal 
solution containing (in mM) 110 d-gluconate, 110 CsOH, 30 CsCl, 5 HEPES, 4 NaCl, 
0.5 CaCl2, 2 MgCl2, 5 BAPTA, 2 NaATP, and 0.3 NaGTP (pH 7.35 with CsOH), and the 
extracellular recording solution was composed of (in mM) 150 NaCl, 10 HEPES, 3 KCl, 
0.5 CaCl2, 0.01 EDTA, 20 d-mannitol and 1 glutamate (pH 7.4 with NaOH). Rapid 
solution exchange was achieved on lifted cells using a two-barrel theta-glass pipette 
controlled by a piezoelectric translator (MXPZT-300; Siskiyou Corporation, Grants Pass, 
OR), and the speed was measured to be 0.4-0.8 milliseconds (10%–90% rise times) 
from the open tip junctional potential. Only cells with current responses of less than 1 
nA were recorded to prevent inaccurate measurement of decay time courses due to 
poor resistance compensation. 
 
2.2.5 Whole cell recording data analysis 
Whole-cell patch-clamp recordings were analyzed using AxoGraph 
(www.axograph.com) to determine response rise time, deactivation kinetics (fit with 
either mono or dual exponential equations), and current amplitude. The deactivation 
time courses of current responses (each averaged from at least five sweeps) were fitted 
using:  
 
Itotal = Ifast (−time/τfast) + Islow(−time/τslow) 
 
where τfast and τslow are the deactivation time constants for the fast and slow 
components, respectively, and Ifast and Islow are the current amplitudes of the fast and 
slow components, respectively. Weighted deactivation time constants were calculated 
using:  
τweighted = τfast(Ifast / Ifast + Islow) + τslow(Islow / Ifast + Islow) 
  
Response amplitudes and τweighted time constants were plotted in GraphPad 
Prism (GraphPad Software v8). Data are presented as mean ± SEM. One and two-way 
 32 
ANOVAs with Tukey post-hoc test were used for statistical comparisons as indicated 
and p < 0.05 was considered significant. 
2.3 Results 
 To investigate functional and pharmacological properties of NMDA receptors 
containing GluN2A gain-of-function mutations, we selected six mutations identified in 
children with epilepsy-aphasia spectrum (EAS) disorders. Mutations are located in the 
agonist binding domain (ABD), linker regions between the ABD and transmembrane 
domains (TMD), or the M2 reentrant loop of the TMD (Figure 2.2). While these 
mutations had previously been characterized as gain-of-function, many properties have 
yet to be determined for all six mutants. 
Glutamate and glycine concentration-response data were measured using two-
electrode voltage-clamp (TEVC) recordings on Xenopus oocytes injected with GluN1 
and GluN2 wild type or mutant mRNA. All GluN2A gain-of-function containing NMDA 
receptors showed increased agonist and co-agonist potencies, except for GluN2A-
N615K (Figure 2.2). GluN2A-N615K to behave like wild type GluN1/2A receptors, which 
is to be expected as the N-to-K mutation relieves sensitivity to Mg2+ block, which has not 
been found to modulate agonist binding and gating properties (Endele et al., 2010; 
Pierson et al., 2014). Data are summarized in Figure 2.2C and NMDA receptors 
containing GluN2A mutations (except for GluN2A-N615K) have significantly increased 
agonist and co-agonist potencies as compared to wild type GluN1/2A. 
The GluN2A-selective negative allosteric modulators (NAMs) bind at the dimer 
interface between GluN1-GluN2 subunits and act to destabilize glycine binding in GluN1 
subunits (Yi et al., 2016). It was unknown whether NAM binding could overcome 
increases in glycine potency seen in GluN2A gain-of-function mutants. We sought to 
determine NAM binding potencies in the presence of 3 µM glycine for the six gain-of-
function mutations using TEVC recordings at recombinant wild type or mutant NMDA 
receptors. NAM concentration response curves mirrored the trend in agonist and co-
agonist EC50 seen in Figure 2.2, with wild type and GluN2A-N615K being the most 
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sensitive, GluN2A-K669N as an intermediate, and GluN2A-N447K, P552R, L812M, and 
M817V as the least sensitive to NAM-mediated inhibition (Figure 2.3).   
Figure 2.2: Characterization of NMDA receptors containing GluN2A gain-of-
function mutations A) Linear and modular representation of a GluN2A subunit with 
locations of gain-of-function mutations (stars) overlaid. NMDA receptor subunits 
contain an amino-terminal domain (ATD), agonist binding domain (ABD), 
transmembrane domain (M1-M4), and carboxy-terminal domain (CTD). B) Glycine 
(left) and glutamate (right) concentration-response curves in the continuous 
presence of 100µM glutamate or glycine, respectively. C) Summary of agonist 
potencies. Data are mean ± SEM from 4-7 oocytes. *Indicates significantly different 
from GluN1/GluN2A (p<0.05 one-way ANOVA corrected for multiple comparisons 
with a Tukey post-hoc test) 
 
 34 
To further probe the reciprocal relationship between glycine and NAM binding, 
we plotted glycine EC50 against TCN-201 IC50 (in the presence of 3 µM glycine) and 
performed a Pearson’s correlation test (Figure 2.4). We found that the data are highly 
orrelated (R2 = 0.98) if GluN2A-P552R is excluded from correlation analysis. When 
GluN2A-P552R values are included, the correlation is less correlated, with a fit of R2 = 
0.80. This indicates that decreased NAM-mediated inhibition of NMDA receptors 
containing GluN2A-P552R subunits cannot be fully described by increases in glycine 
potency.  
Due to the disparity in NAM IC50 vs glycine EC50 correlation seen in NMDA 
receptors containing GluN2A-P552R mutations, we sought to delineate whether this 
difference is due to alterations in NAM binding affinity (Kb) or the negative allosteric 
relationship between NAM and glycine binding (α). In our operational model, the 
dissociation constant for agonist binding (Ka) is modulated by a factor of 1/ α, where α is 
the allosteric constant, and accordingly antagonist binding (Kb) is modulated by the 
same factor upon agonist binding (Christopoulos and Kenakin 2002). We assume that 
Figure 2.3: Inhibition by GluN2A-selective NAMs. A) Representative traces 
showing concentration-dependent inhibition by MPX-004 for GluN2A wild type (left) 
and GluN2A-P552R (right). B) NAM concentration-response curves. TCN-201 (left) 
is maximally soluble at 5µM, MPX-004 10µM (middle), and MPX-007 30µM (right). 
For each NAM, data are mean ± SEM from 5-17 oocytes.  
 
 35 
the negative, reciprocal relationship between NAM and glycine binding doesn’t affect 
glutamate and glycine agonist efficacies (Figure 4A) (i.e. NAM destabilization of glycine 
binding doesn’t affect channel conductance or open probability). Negative allosteric 
modulation is defined as 0 < α <1, neutral modulation alpha = 1, positive α>1, and 
competitive inhibition α=0, as is the case for the canonical Schild equation. 
Furthermore, the dose ratio (DR) is defined as the ratio of EC50 values in the presence 
and absence of antagonist (EC50 ‘).  
We performed Schild analyses of glycine concentration-response curves in the 
increasing presence of TCN-201 (Figure 2.5) and fit the all the data using a global 
nonlinear regression model (Hansen et al., 2012). Using this analysis for wild type 
GluN1/2A c receptors, we arrived at a TCN-201 binding affinity (Kb) equal to 17nM with 
an allosteric constant of 0.004, indicating that TCN-201 can at most cause a 250 (1/α) 
fold increase in glycine EC50 (i.e. increase glycine potency from 1µM to 250µM). 
To determine possible differences in binding affinity or allosteric interactions, we 
then repeated Schild analyses on select representative GluN2A gain-of-function 
containing NMDA receptors (GluN2A-N615K, GluN2A-L812M, GluN2A-P552R). While  
Figure 2.4: Correlation between glycine and NAM potencies. A) Increases in 
glycine potencies seen in NMDA receptors containing GluN2A gain-of-function 
mutations correlate with decreases in NAM potency, except for GluN2A-P552R. B) 
NMDA receptor crystal structure (PDB ID 4PE5) with TCN-201 (red), glutamate and 
glycine (blue), and GluN2A gain-of-function mutation locations indicated (black). 
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Kb and α values for GluN2A-N615K and GluN2A-L812M are similar to wild type 
GluN1/2A, NMDA receptors containing GluN2A-P552R have a markedly different 
binding affinity and allosteric constant (Figure 2.6). This indicates that NMDA receptors 
harboring GluN2A-P552R mutations have a conformationally distinct dimer interface 
(i.e. where GluN2A-selective NAMs bind) in comparison to wild type GluN1/2A  
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Figure 2.5: Evaluation of allosteric inhibition of GluN2A-containing NMDA 
receptors. A) Operational model of allosteric inhibition without altering receptor 
efficacy (E). A is agonist, R is receptor, and B is antagonist. Dissociation constants 
for agonist (Ka) and antagonist (Kb) are modulated by the allosteric constant (α), 
which reflects the reciprocal relationship between glycine and NAM binding. B) 
Glycine concentration-response curves in the presence of increasing concentrations 
of TCN-201. Dose-response data are simultaneously fitted to the Hill and dose ratio 
(DR) equations using global nonlinear regression (left). TCN-201 binding in the 
absence of glycine is calculated at 17.2 ± 0.002 nM with an allosteric constant of 
0.004 ± 0.002. The Schild plot (right) illustrates the difference in allosteric constants 
of a competitive inhibitor (α=0) and TCN-201 (α=0.004). Data are mean ± SEM from 
4-6 oocytes, repeated on three separate days, for a total of 12-24 oocytes for each 
glycine response-curve. 
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Figure 2.6: Schild analysis of NMDA receptors containing GluN2A gain-of-
function mutations. Glycine concentration responses curves in the presence of 
increasing concentrations of TCN-201 for GluN1-a/GluN2A-N615K (A), GluN1-
a/GluN2A-L812M (B), and GluN1-a/GluN2A-P552R (C), left. Schild plots are 
plotted against GluN1-a/GluN2A wild type (right). GluN1-a/GluN2A-P552R TCN-
201 binding affinity is increased by 10-fold (C). Data are mean ± SEM from 4-6 
oocytes, repeated on three (GluN1-a/GluN2A, GluN1-a/GluN2A-N615K, GluN1-
a/GluN2A-L812M) or four (GluN1-a/GluN2A-P552R) separate days, for a total of 
12-24 oocytes for each glycine response-curve. 
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receptors. Therefore, a mutation in the pre-m1 linker region transduces a 
conformational change in the dimer interface, which was unexpected. 
Since synaptic transmission occurs in the millisecond timescale, we sought to 
characterize kinetics of activation, deactivation, and the extent of NAM-mediated 
inhibition during brief exposures to glutamate suing whole-cell patch-clamp recordings. 
HEK293 cells transfected with GluN1-GFP and GluN2A wild type, or mutant subunits, 
were exposed to 1mM glutamate for 3-5ms in the continuous presence of 10 µM glycine 
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(Figure 2.7). All mutant subunits, except GluN2A-P552R, had comparable rise times as 
seen in wild type GluN1/2A (Figure 2.7D). Conversely, NMDA receptors harboring 
GluN2A-N447K, P552R, K669N, L812M, or M817V subunits had prolonged deactivation 
kinetics (Figure 2.7B & C). 
We then assessed glycine sensitivity and NAM-mediated inhibition at both low 
and intermediate physiological levels of glycine (i.e. 0.3 and 3µM, respectively). We 
found that increases in glycine potency (i.e. lower EC50 values compared to wild type, 
see Figure 2.2) measured using TEVC recordings during steady-state for receptors with 
GluN2A-N447K, P552R, K669N, L812M, or M817V subunits were not observed in 
synaptic-like activation experiments (Figure 2.8 A&D). Instead, NMDA receptors 
harboring gain-of-function mutations showed similar response ratios to 0.3 and 10µM 
glycine as NMDA receptors expressing GluN2A wild type subunits (Figure 2.8A & D), 
albeit except for GluN2A-P552R mutants. Similarly, 3µM NAM was able to fully inhibit 
NMDA receptors containing GluN2A gain-of-function subunits, except for those 
containing GluN2A-P552R subunits. NMDA receptors with GluN2A-P552R subunits 
were most sensitive to 3µM MPX-004 and 007 (68 and 74% inhibition, respectively) as 
compared to TCN-201 (45% inhibition) (Figure 2.8B & E). 
 
Figure 2.7: Kinetic properties during synaptic-like activation of NMDA 
receptors with GluN2A gain-of-function mutations. Representative traces 
normalized to response amplitude of GluN1/GluN2A NMDA receptors with synaptic-
like pulses of glutamate, in the continuous presence of 10µM glycine. A) 
GluN1/GluN2A wildtype, N615K, and K669N deactivate on a faster timescale as 
compared to B) N447K, P552R, L812M, and M817V-containing NMDA receptors. C) 
Summary of deactivation kinetics and D) rise time to peak amplitude of wild type 
GluN1/GluN2A and all six mutants. Data are mean ± SEM from 13-33 HEK293T 
cells 
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2.4 Discussion  
In this work, we have assessed the extent to which GluN2A-selective NAMs can 
inhibit NMDA receptors containing GluN2A gain-of-function mutations identified in 
children with epilepsy-aphasia spectrum (EAS) disorders. This is a proof-of-concept 
study aimed at answering whether GluN2A-selective NAMs could potentially be a viable 
therapeutic strategy to target and ameliorate hyperactive GluN2A-containing NMDA 
receptors. Children with EAS are prescribed general central nervous system 
depressants to treat severe epilepsy during slow-wave sleep, and theoretically could 
benefit from a more targeted approach with fewer off-target effects.  
NMDA receptors harboring GluN2A subunits with gain-of-function mutations 
show various forms of gain-of-function attributes, including increased agonist potencies, 
decreased sensitivity to endogenous inhibitors, and increases in channel open time and 
open probability (Endele et al., 2010; Yuan et al., 2014; Swanger et al., 2016; Chen et 
al., 2017; Ogden et al., 2017; Xu et al., 2018). First, we characterized differences in 
glutamate and glycine potency under steady-state conditions using two-electrode 
voltage-clamp electrophysiology. We found that, with the exception of GluN2A-N615K 
mutants, all NMDA receptors with GluN2A gain-of-function mutations have both 
increased glutamate and glycine potencies (Figure 2.2).  
Since GluN2A-selective NAMs inhibit NMDA receptor activation by destabilizing 
glycine binding, it was unknown whether these NAMs could overcome increases in 
glycine potency seen in the gain-of-function mutants. GluN2A-N615K NMDA receptors 
Figure 2.8: Agonist and NAM potencies during synaptic-like activation of 
NMDA receptors harboring GluN2A gain-of-function mutations. A) 
Representative whole cell recordings of responses elicited by brief glutamate 
exposure (1 mM for 3-5ms) in the continuous presence of 0.3 or 10 µM glycine for 
NMDA receptors containing GluN2A-WT (left), -L812M (center), and –P552R (right). 
B) Representative recordings in mid-range physiological glycine and extent of 3 µM 
TCN-201 or C) MPX-004 inhibition in GluN2A-WT or –P552R containing NMDA 
receptors. D) Summary plot of 0.3 and 3 µM glycine response normalized to 10 µM 
glycine. E) Summary plot of 3 µM NAM inhibition in 3 µM glycine for all mutants. Data 
are mean ± SEM from 4-10 HEK293 cells. *Indicates significantly different from 
GluN1/GluN2A ratio of 0.3 to 10 µM glycine (p<0.05 one-way ANOVA corrected for 
multiple comparisons with a Tukey post-hoc test). 
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served as our positive control because the only gain-of-function feature of these 
receptors is a Mg2+ relief, which we did not predict to affect NAM binding or inhibition. 
We found that all NMDA receptors containing GluN2A gain-of-function mutations were 
inhibited by NAMs, but with reduced NAM potencies that reflected increases in glycine 
potency (i.e. receptors with increased glycine binding show decreased NAM binding). 
To assess possible differences in correlation between NAM and glycine binding, we 
analyzed the relationship between glycine EC50 vs TCN-201 IC50 (in 3µM glycine) 
(Figure 2.4). We found that all mutants showed high correlation (R2 = 0.98) between 
glycine EC50 and TCN-201 IC50 except for NMDA receptors harboring GluN2A-P552R. 
Inclusion of GluN2A-P552R agonist and NAM potency into our correlation plot shifted 
the Pearson correlation fit from 0.98 to 0.8. This indicates that the GluN2A-P552R 
mutation may disrupt NAM binding or the allosteric association between NAM and 
glycine destabilization. 
Using Schild analysis of glycine concentration-response curves in the presence 
of increasing antagonist (TCN-201), we calculated antagonist binding affinity (KB) in the 
absence of glycine, along with the allosteric constant, which quantifies the negative 
relationship between NAM and glycine binding (Figure2.5). In addition to wild type 
GluN2A containing NMDA receptors, we performed these experiments on a subset of 
the representative mutants, including GluN2A-N615K, L812M, and P552R (Figure 2.6). 
We found that NMDA receptors harboring GluN2A-P552R subunits have a 10-fold 
decrease in NAM binding affinity, indicating that this mutation causes a conformational 
change in the dimer interface where NAMs bind. All other mutants showed unaltered 
antagonist binding affinities (Figure 2.6).  
Since synaptic events occur on a millisecond timescale, we assessed kinetic 
properties of GluN2A gain-of-function mutants, agonist sensitivity, and NAM-mediated 
inhibition under non-equilibrium conditions in both low (0.3 µM) and intermediate (3 µM) 
estimates of physiological glycine to characterize potential differences in NAM 
sensitivities to glycine. HEK293 cells transfected with GluN1 and GluN2A subunits, with 
or without gain-of-function mutations, were activated by brief (3-5ms) pulses of 
glutamate in the continuous presence of glycine with or without 3 µM NAM.  
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 In the absence of NAM, the amplitude ratio of 0.3 and 3 µM glycine to 10 µM 
glycine was equivalent to the ratios at wild type GluN1/2A receptors for all gain-of-
function mutants, except NMDA receptors containing GluN2A-P552R subunits (Figure 
2.8). Therefore, the increases in glycine potency measured during equilibrium 
conditions do not reflect those seen in non-equilibrium conditions in NMDA receptors 
harboring GluN2A gain-of-function mutations.  
The lack of agreement between glycine potencies in equilibrium and non-
equilibrium measurements could be attributed to the presence and absence, 
respectively, of NMDA receptor desensitization during the measurements. During 
equilibrium or long exposure to agonist, NMDA receptors can desensitize, which results 
in channel closure while agonists are still bound. As receptors exit the desensitized 
state with bound agonist, they can either re-enter the desensitized state, enter the open 
state, or the agonists can unbind (Figure 2.9). The desensitized state therefore acts as 
a conformational “sink” that effectively slows agonist unbinding. Consequently, the 
agonist potency (i.e. apparent affinity) will be higher in the presence of desensitization 
compared to in the absence of desensitization. 
Despite differences in glycine potency between steady-state and synaptic-like 
activation, all mutants, except for our positive control (GluN2A-N615K), displayed 
prolonged deactivation time courses compared to wild type receptors (Figure 2.7). 
Therefore, while nearly all gain-of-function mutants showed reduced sensitivity to 
glycine during synaptic-like events, gain-of-function attributes may be reflected in total 
Figure 2.9: Fundamental kinetic model of NMDA receptor activation and 
deactivation. The receptor, R, has two binding sites for agonist, A. O* is the open 
channel state while A2D is the desensitized state. β and α represent the opening and 
closing rates, kon and koff the binding and unbinding rates, and kd and kr are the rates 
of desensitization and resensitization. Adapted from Lester and Jahr 1992. 
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charge transfer. Furthermore, increases in open probability (i.e. increased agonist 
efficacy) were not assessed but would also contribute to gain-of-function properties.  
All gain-of-function containing NMDA receptors, except those harboring GluN2A-
P552R subunits, were fully inhibited by 3µM TCN-201, MPX-004, and MPX-007. The 
greater extent of NAM inhibition under synaptic-like events reflect the data seen with 
apparent decreases in glycine potency. These data could be explained by a lack of 
NMDA receptor desensitization and therefore an apparent decrease in glycine potency 
and an increase in NAM potency fit well together. To assess desensitization 
contribution, future experiments should be centered on longer agonist and NAM 
exposure to determine differences in peak and steady-state response amplitudes. 
Together, these data support the dimer interface between GluN1 and GluN2A 
subunits as an attractive therapeutic target for GluN2A gain-of-function disorders. Of the 
six representative gain-of-function mutants tested, only one caused changes in the 
dimer interface. This indicates that most GluN2A gain-of-function mutations do not alter 
the conformation of the dimer interface, which allows NAMs to inhibit a wide-range of 
gain-of-function phenotypes. Furthermore, despite the reduced binding affinity, NAMs 
were still able to inhibit NMDA receptors containing GluN2A-P552R subunits. 
Additionally, NAMs were more effective inhibitors in physiological time-scales (i.e. 
synaptic-like events), which further purports the dimer interface as an attractive 
therapeutic target to ameliorate hyperactive NMDA receptors containing GluN2A gain-
of-function mutations.  
3.0 Quantification of excitotoxicity in cortical neurons transfected with GluN2A gain-of-
function mutations 
 
3.1 Introduction 
 The subunit composition of NMDA receptors is tightly regulated both temporally 
and spatially, which imparts a high degree of NMDA receptor pharmacological diversity 
during development. During development of the cortex, GluN2A subunit expression 
gradually increases and integrates into the synapse (Monyer et al., 1994; Sheng et al., 
1994). This developmental switch also occurs in vitro during rodent primary cortical cell 
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and organotypic culture development, where GluN2A expression begins postnatally 
around day in vitro (DIV) 7 and extends through 21 (Li et al., 1998; Barria and Malinow, 
2002). 
 As GluN2A subunits integrate into the synapse, triheteromeric 
GluN1/GluN2A/GluN2B receptors become more prevalent. Triheteromeric receptors do 
not simply adopt intermediate properties between diheteromeric GluN1/GluN2A and 
GluN1/GluN2B NMDA receptors. Instead, GluN1/GluN2A/GluN2B receptors show 
kinetic properties dominated by GluN2A (i.e. faster decay kinetics and increased open 
channel probability) (Sun et al., 2017). GluN2A subunit expression is biologically 
documented as a developmental switch to associative learning (Dumas 2005). Indeed, 
GluN2A knock-out mice show altered synaptic plasticity and impaired learning 
(Andreescu et al., 2011; Sakimura et al., 1995; Zhao and Constantine-Patron, 2007). 
This indicates that GluN2A expression is important for time-sensitive synaptic 
integration of sensory inputs. 
 Due to GluN2A’s role in dictating the kinetic window for associative learning, it is 
no surprise that gain or loss-of-function mutations in GluN2A cause disruptions in 
learning processes. In fact, the etiology of certain severe forms of epilepsy-aphasia 
spectrum (EAS) disorders are associated with de novo missense mutations in GluN2A. 
Pediatric patients with EAS have seizures during sleep, which can result in speech 
impairments and, in severe cases, general intellectual disability with developmental 
delay (XiengWei et al., 2018). 
Recently, Strehlow and colleagues (2018) have found a correlation between the 
location of GluN2A mutations and their impact on disease severity. They assessed a 
cohort of 248 individuals, 92 of which were from unpublished screens and another 156 
from previous reports. Both groups were identified to have “likely” pathogenic variants 
for which the criteria includes: de novo mutations absent in controls, novel missense 
mutations located in a genomic region already classified as “pathogenic” where 
variation is absent in controls, confirmative functional studies that are in disagreement 
from controls, or mutations present in three or more members of a family but are absent 
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from controls (controls were over 120,000 people without severe pediatric disease 
gathered from gnomAD.broadinstitute.org). 
In their cohort, sex was divided similarly among variants (45% female, 55% 
male). The youngest individual was 11 months old and the eldest was 71 years old, with 
a median age of eight years. Nearly half of the cohort had de novo GRIN2A (gene 
encoding GluN2A) mutations, the rest belonging to familial inheritance from 36 different 
families (127 individuals). 62% of individuals showed intellectual disability, 88% 
presented with epilepsy, 92% had speech disorders, and interestingly, 75% of 
individuals had no MRI abnormalities. They then identified phenotypic correlations when 
separating the cohort into individuals with mutations in the transmembrane domain 
(TMD) or linker regions from those with mutations in the agonist binding domain (ABD) 
or amino-terminal domain (ATD). Individuals with mutations in the TMD or linker region 
show more severe intellectual disability than those with mutations in the ABD or ATD. 
Furthermore, individuals with documented brain volume loss on MRIs had mutations in 
either the TMD or linker regions, whereas individuals with a mutation in the ABD or ATD 
showed no volume loss. Both groups showed similar EEG patterns but individuals with 
mutations in the TMD or linker regions presented with epileptic spasms, whereas 
individuals with mutation in the ABD or ATD were more likely to present with focal 
seizures (Strehlow et al., 2018). 
Here, we sought to characterize cellular toxicity associated with expression of 
GluN2A gain-of-function mutations located in the TMD and linker regions. As these 
mutations cause central nervous system atrophy in humans, we hypothesized that 
transfection of these GluN2A gain-of-function mutants would be neurotoxic. Along this 
rationale, Ogden and colleagues (2017) transfected neurons in culture with GluN2A-
P552R (pre-m1 linker region) subunits, which caused significant neural blebbing, a 
precursor of neural cell death. Furthermore, they were able to rescue GluN2A-P552R 
mediated cell death by concomitant treatment with memantine, a non-selective NMDA 
receptor open channel blocker.  
We have found that all gain-of-function transfected cells show a slight increase in 
blebbing compared to GluN2A-WT controls, and one mutant, GluN2A-L812M, caused 
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significantly increased blebbing. However, this minimal blebbing was unable to be 
rescued by GluN2A-selective allosteric modulators (NAMs) or memantine. We conclude 
that excitotoxicity, measured through neurite blebbing, is not a direct consequence of 
NMDA receptors containing GluN2A gain-of-function mutants.  
3.2 Methods 
3.2.1 Coverslip preparation 
 Glass coverslips of 12mm in diameter (Fischer Scientific) were shaken (200 
rotations per minute) overnight, while immersed in sand to facilitate etching. The 
following day, coverslips were washed three times with sterile water and then lightly 
agitated with 1M HCl overnight to remove grease. The next day, coverslips were 
washed three times with sterile water followed by a final wash with 80% ethanol and 
then were left overnight in the tissue culture hood to dry.  
 Coverslips were moved to 24-well plates a couple days before dissection and 
incubated in 80% ethanol for 20 minutes. Coverslips were then washed three times with 
sterile Hanks’ Balanced Salt Solution – Ca2+ and Mg2+ (HBSS-, Life Technologies) 
before being coated in 0.2mg/mL high molecular weight poly-D-lysine (70-150kDa, 
Sigma) dissolved in 0.22µm filtered 1M borate buffer (pH 8.7). Plates containing glass 
coverslips were incubated overnight (370C, 5%CO2) and then washed three times with 
HBSS-. Plates were then incubated in 10µg/mL laminin (R&D Systems, Culturex Mouse 
Laminin I PathClear®) in ice-cold HBSS- in a 40C refrigerator until needed (up to a 
month). 
3.2.2 Mouse brain dissection and plating 
 Postnatal day 0-1 (P0-1) C57BL/6 mice of either sex were decapitated in 
accordance with the Institutional Care and Animal Use Committee and Department of 
Laboratory Animal Resources at the University of Montana. The brain was rapidly 
dissected and promptly emerged in ice-cold Hibernate AB complete media (Brain 
Bits®). Following dissection of hippocampi or cortices, tissues were incubated in 140 
units of papain (Worthington Biochemicals) dissolved in Hibernate A minus calcium 
(BrainBits®) at 370C for 20 minutes while shaking at 450 rotations per minute. A 
maximum of two pairs of hippocampi and one pair of cortices were incubated in 140 
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units of papain, preparations were scaled according to amount of tissue being 
processed. 
 Following digestion with papain, tissue was moved to a 15mL conical tube 
containing room temperature Hibernate AB complete media (Brain Bits®). Tissue was 
triterated ten times with a glass Pasteur pipette then left for three minutes to allow the 
tissue to settle to the bottom of the tube. The supernatant containing single cells was 
collected and moved to another 15mL conical tube. This process was repeated three 
times, then the cell suspensions were spun down at 1100 rpm (200 x g) for 3 minutes at 
room temperature. Supernatant was removed and cells were resuspended in 1mL of 
neuronal NBCo-Culture media (BrainBits®) containing 25µM sterile-filtered 10mM 
glutamate and 1x Penicillin/Streptomycin (Life Technologies). Cell counts were 
performed by combining 10 µL cell suspension and 10 µL trypan blue solution 
(Invitrogen) and plated at a density of 2e5 cells/mL. A 100% media change was 
performed 24 hours after plating with NBCo-Culture with 25 µM glutamate. Half of the 
media was changed four days later with NBCo-Culture media. Another complete media 
change is performed at day in vitro (DIV) 8-9 with NBActiv4 (BrainBits®) and 50% 
media changes are maintained every four days, or earlier if the media becomes acidic 
(i.e. turns yellow).  
3.2.3 Neuronal transfection 
 On DIV17 primary neuronal cultures were transfected with Neuromag (OZ 
Biosciences®). For each well of a 24-well plate, 100 µL of NBActiv4 was combined with 
0.75 µg DNA. DNA, prepared with endotoxin-free maxi-prep kits (Qiagen®), included 
green-fluorescent protein (GFP), wild type GluN2A, GluN2A-N615K, GluN2A-L812M, 
and GluN2A-P552R, all driven by a calcium-calmodulin kinase promoter. GFP and 
GluN2A subunits were combined in 1:1 ratio for a total of 0.75 µg DNA/well. DNA and 
NBActiv4 solution was then combined with 1.5 µL Neuromag and let to incubate at room 
temperature for 20 minutes. After incubation, the plate was moved to the magnetic plate 
and incubated for 20 minutes (370C, 5%CO2) before removing the magnetic plate from 
the tissue culture incubator. After 4-6 hours following transfection, media was removed 
and half was aliquoted and combined with fresh NBActiv4 with either vehicle (0.1% 
 49 
DMSO), 3 µM MPX-007, 30 µM MPX-007, or 50 µM memantine (DMSO controlled in all 
conditions). Three days following transfection, neurons were fixed in 4% 
paraformaldehyde and moved to a 40C refrigerator until further processing (up to a 
week). 
3.2.4 Preparation of slides for microscopy 
 Paraformaldehyde was removed from 24-well plates containing neuron-coated 
coverslips and washed three times with HBSS containing Ca2+ and Mg2+ (Life 
Technologies). Coverslips were then plated on slides (Shandon ColorFrost Plus,Thermo 
Fisher Scientific) with DAPI Vectaschield mounting medium (Vector Laboratories) and 
sealed with clear nail polish. Slides were stored in a 40C refrigerator until processing. 
3.2.5 Confocal imaging and analysis of neuronal cultures 
 Neurons were imaged using a Zeiss® 880 confocal laser scanning microscope 
(Zeiss LSM 880). Images were obtained at 20x magnification and z-stacks were 
established to have 50% overlap between 0.88µM sections. Z-stacks were analyzed by 
performing a maximum intensity projection (Fiji). The image was then converted into a 
binary bit image by setting the threshold to 2x the background noise. Neuronal blebbing 
was then quantified using the “analyze particles” feature in Fiji. Two measurements 
were taken using this plug-in feature, the first being the total cell area (0-infitie µM; 
circularity 0-1), and the second quantifying neural cell blebbing (3-infitie µM; circularity 
0.35-1). 
 Percent blebbing was calculated as the ratio of the total blebbing area to the total 
cell area. Only neurons showing at least three branch points were included for analysis. 
Values were plotted using Prism8® (GraphPad) and data were analyzed using one-way 
ANOVA with mutants compared to wild type, followed with a Tukey post-hoc test and 
regarded as significant if p<0.05. 
3.3 Results 
 In this work we sought to characterize cellular toxicity resulting from transfection 
of GluN2A gain-of-function mutants. We were able to detect expression of subunits in 
excitatory cells by use of plasmids containing green fluorescent protein (GFP) or 
GluN2A subunits, both driven by a calcium-calmodulin kinase (CaMKII) promoter. As 
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CaMKII is only expressed in excitatory neurons in the hippocampus (Jones et al., 1994), 
we were able to ask whether expression of mutated GluN2A subunits mediate 
excitotoxicity in cultured excitatory neurons. We isolated cortical neurons from postnatal 
day 0-1 (P0 -1) mice and cultured neurons for a total of 20 days, with transfection of 
relevant subunits on day in vitro 17 (DIV 17) (Figure 3.1A). After transfection, neurons 
were incubated in the presence or absence of MPX-007, or memantine, to protect 
neurons from potential cytotoxicity caused by GluN2A gain-of-function mutants. 
 All gain-of-function mutants showed a minimal increase in neurite blebbing 
compared to GluN2A-WT transfected controls, though only toxicities resulting from 
GluN2A-L812M transfections were considered significant (Figure 3.1B & C) (GluN2A-
WT 0.5 ± 0.2%, GluN2A-P552R 2.0 ± 0.5%, GluN2A-N615K 2.5 ± 0.5%, GluN2A-
L812M 2.8 ± 0.5%, one-way ANOVA with Tukey post-hoc test; p < 0.05). Furthermore, 
this significant increase in cellular toxicity by transfection of GluN2A-L812M subunits 
could not be rescued by NAM or memantine treatment (Figure 3.1B & C). 
 Though the blebbing quantified in GluN2A-P552R transfected cells did not show 
significantly different blebbing compared to GluN2A-WT transfected cells, the moderate 
increase in blebbing was significantly reduced by both 3 and 30 µM MPX-007 (0.4 ± 
0.1% and 0.2 ± 0.1%, respectively; one-way ANOVA with Tukey post-hoc test; p < 0.05) 
(Figure 3.1B & C). Similarly, 3 µM MPX-007 showed moderate protection against 
blebbing in GluN2A-L812M (1.9 ± 0.5%), but not GluN2A-N615K (2.2 ± 0.4%) 
transfected cells (Figure 3.1B & C). The opposite trend was seen for 30 µM MPX-007 
where there was a moderate rescue in in GluN2A-N615K (1.5 ± 0.4%), but not GluN2A-
L812M (2.5 ± 0.6%) transfected cells. 
 While 50 µM memantine had no significant effect on ameliorating moderate 
cytotoxicity seen in GluN2A gain-of-function transfections, there is a trend in decreasing 
cell blebbing in GluN2A-P552R and GluN2A-L812M transfected neurons (GluN2A-
P552R 0.6 ± 0.2% and GluN2A-L812M 1.5 ± 0.4%) As we expected, memantine 
showed no trend in protecting neurons harboring GluN2A-N615K mutations (GluN2A-
N615K 2.0 ± 0.9%). This served as our negative control because the N-to-K mutation 
prevents positively charged species, like memantine, from binding in the channel pore.  
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Together, these data suggest that toxicity associated with GluN2A gain-of-
function mutations cannot be explained by a straight-forward mechanism that involves 
excitotoxicity. These gain-of-function mutations were solely expressed in excitatory 
neurons, due to expression being driven by a CaMKII promoter, and yet did not cause 
significant blebbing, except for GluN2A-L812M. Therefore, the gain-of-function 
attributes seen in NMDA receptors harboring these mutations do not promote neuronal 
cell death due to excitotoxicity.  
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3.4 Discussion 
 In this study, we evaluated whether cortical neurons transfected with select 
GluN2A gain-of-function mutants would trigger excitotoxicity. We chose to evaluate 
gain-of-function mutations located in the transmembrane domain (TMD) or linker 
regions because these locations are correlated with the most severe outcomes for 
epilepsy-aphasia spectrum (EAS) disorders (Strehlow et al., 2018). These severe 
phenotypes include brain atrophy, continuous spike and wave during slow-wave sleep, 
and an earlier onset of disease progression.  
Since NMDA receptors harboring GluN2A gain-of-function mutations are more 
readily activated, we presumed that expression of these subunits in neurons could 
result in excitotoxicity due to amplified influx of Ca2+ by NMDA receptors. To measure 
the extent of potential excitotoxicity, we quantified neurite blebbing, a cellular marker of 
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Figure 3.1: Measurement of excitotoxicity in cortical neurons expressing 
GluN2A gain-of-function mutants. A) Timeline of cortical neuron isolation, culture, 
and transfection. B) Representative images of mature cortical neurons transfected 
with GFP and GluN2A-WT or GluN2A gain-of-function subunits. Following 
transfection, neurons were either incubated in 0.1% DMSO, 3 or 30 µM MPX-007, or 
50 µM memantine. C) Summary plots quantifying neural blebbing normalized to total 
cell area. GluN2A-L812M subunits showed significant blebbing compared to neurons 
transfected with GluN2A-WT subunits. *Indicates significantly different from 
GluN1/GluN2A neurite blebbing (p<0.05 one-way ANOVA corrected for multiple 
comparisons with a Tukey post-hoc test). 
* 
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excitotoxicity. We found that neurons transfected with GluN2A subunits with mutations 
in the TMD or linker regions all caused cell blebbing (Figure 3.1B & C). However, while 
the modest increase in cellular toxicity was relatively equivalent among mutant 
transfected cells, only neurons expressing GluN2A-L812M subunits showed statistically 
significant blebbing compared to GluN2A-WT controls. From these data we conclude 
that there is no evidence for pronounced excitotoxicity resulting from expression of 
severe GluN2A gain-of-function mutants in primary cortical cultures.  
To further define whether the minimal cell blebbing was a result of overactive 
NMDA receptors harboring GluN2A gain-of-function mutations, we assessed if blebbing 
could be rescued by MPX-007, a GluN2A-selective negative allosteric modulator (NAM), 
or memantine, a non-selective NMDA receptor allosteric antagonist. If blebbing was a 
consequence of excitotoxicity from hyperactive NMDA receptors, then NMDA receptor 
antagonists should ameliorate the resulting excitotoxicity.  
We found that both 3 and 30 µM MPX-007 were able to significantly reduce 
blebbing seen in neurons harboring GluN2A-P552R subunits, albeit these subunits did 
not cause significant blebbing compared to GluN2A-WT transfections. We did not find a 
significant reduction in bleb formation after treatment with NMDA receptor antagonists in 
neurons transfected with other GluN2A gain-of-function mutations (i.e. GluN2A-N615K 
and -L812M). Since transfections of GluN2A gain-of-function mutations do not cause 
pronounced excitotoxicity, which is sensitive to NMDA receptor antagonist treatment, 
we speculate that NMDA receptor-mediated excitotoxicity is not a major determinant of 
the disease pathology caused by these de novo mutations in EAS disorders. 
 It is possible that these GluN2A subunits with gain-of-function mutations are not 
successfully trafficked to the surface or properly localized at the cell surface. This could 
explain why excitotoxicity does not result from expression of GluN2A gain-of-function 
mutations. Future studies should be directed at quantifying both intracellular and cell 
surface expression of these subunits. If subunits are not reaching the surface, it is 
possible that the disease phenotype results from a lack of GluN2A subunit presence. 
This deduction would fit into the observation that both GluN2A loss- and gain-of-function 
mutations cause EAS. Alternatively, the detrimental effects of GluN2A gain-of-function 
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mutations could be more pronounced in other cell types, like subpopulations of 
inhibitory interneurons. In the case of interneurons, if mutations cause a loss-of-function 
phenotype, say by deficient trafficking to the membrane, then the excitatory/inhibitory 
balance would shift towards excitotoxicity. This could serve as a potential mechanism to 
explain seizure activity seen in both GluN2A gain and loss-of-function mutations.  
4.0 Quantification of excitotoxicity in CA1 pyramidal neurons expressing GluN2A gain-
of-function mutants 
4.1 Introduction 
Seizures result from the hypersynchronous discharge of a population of neurons, 
a consequence of hyperexcitable neurons. Hyperexcitability can result from various 
mechanisms including increased excitatory neurotransmission, decreased inhibitory 
drive, changes in the extracellular ionic milieu (i.e. increases in external K+), and/or 
alterations in ion channel function. All of these mechanisms act to shift the excitatory 
and inhibitory balance to a more excitable state. 
 
Gain-of-function mutations in GRIN2A can cause increases in NMDA receptor 
agonist potency, increased channel open time and probability, and an increase in the 
duration of channel closure, among other facets that promote hyperexcitability (Endele 
et al., 2010; Yuan et al., 2014; Swanger et al., 2016; Chen et al., 2017; Ogden et al., 
2017; Xu et al., 2018). These states are thought to promote neuronal hyperexcitability 
by increasing the likelihood of NMDA receptor activation, and for some GRIN2A 
mutants, also increasing the duration of NMDA receptor channel opening. Since NMDA 
receptors are permeable to mono- and divalent cations, increases in channel open 
probability and duration can result in a substantial intracellular increase of positive ions 
which can promote neuronal depolarization. As this permeation spreads throughout the 
neuron, local depolarizations can summate and trigger an action potential. One can 
imagine how this process could proceed in nearby excitatory neurons to disrupt the 
excitatory/inhibitory balance, and lead to seizure activity. 
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  As epilepsy is a primary outcome of GRIN2A mutations, it seems probable that 
GRIN2A gain-of-function mutations can lead to seizure disorders due to NMDA 
receptor-mediated increases in hyperexcitability. However, GRIN2A loss-of-function 
mutations also cause epilepsy-aphasia spectrum disorders (EAS) (Gao et al., 2017; 
Strehlow et al., 2018). Recently, Salmi and colleagues (2019) generated GRIN2A 
knock-out mice and characterized social deficits and EEG abnormalities during the first 
two months of postnatal development. They found that, compared to wild-type 
littermates, GRIN2A knock-out mice showed impaired verbal communication (measured 
by frequency and type of ultrasonic vocalization) that peaked in severity between 
postnatal day six and eight. Additionally, they identified increased spontaneous spike-
wave discharges during slow-wave sleep, a common theme in EAS disorders, which 
disrupted sleep duration and quality (measured by the number of transitions between 
wakefulness, slow-wave, and paradoxical sleep per hour) at one month of age. While 
sleep quality recovered by two months of age, spike-wave discharges were present in 
mice throughout the study (up to two months). Interestingly, GRIN2A-/+ heterozygotes 
did not show any differences in behavior or EEG patterns from wild-type littermates.  
 
  These data indicate that the GRIN2A pathophysiology of EAS disorders is more 
nuanced than anticipated. As both GluN2A loss and gain-of-function mutants result in 
EAS disorders, it is unknown whether seizures are a direct result of excitotoxicity arising 
from neurons expressing these mutations, or if seizures are largely the result of faulty 
network refinement during development. Here we have sought to delineate this 
relationship by assessing neuronal blebbing and firing in organotypic slices transfected 
with wild type GluN2A, GluN2A-L812M, or GluN2A-P552R subunits. We found that cells 
transfected with GluN2A-P552R subunits do not bleb more than neurons transfected 
with GluN2A-WT subunits. In contrast, GluN2A -L812M transfected neurons showed 
significant blebbing that could be rescued by treatment with memantine. Furthermore, 
pyramidal neurons transfected with GluN2A-WT, -P552R, or -L812M subunits did not 
exhibit different firing from un-transfected controls. These data indicate that 
excitotoxicity is not the primary driver of EAS disease pathology. 
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4.2 Methods 
4.2.1 Mouse brain dissection, cutting, and plating 
Postnatal day 7-8 (P7-8) C57BL/6 mice of either sex were anesthetized with 
isoflurane and decapitated in accordance with the Institutional Care and Animal Use 
Committee and Department of Laboratory Animal Resources at the University of 
Montana. The brain was rapidly dissected and promptly emerged in ice-cold, sterile-
filtered, low Na+ artificial cerebral spinal fluid, containing in mM: 1 CaCl2, 10 D-Glucose, 
4 KCl, 5 MgCl2, 26 NaHCO3, 234 Sucrose and 0.1% volume/volume phenol red 
solution. Prior to decapitation, the low Na+ artificial cerebral spinal fluid was bubbled 
with carbogen (5% CO2 and 95% O2) for 20 minutes while submerged in ice.  
The whole brain tissue was incubated in ice-cold low Na+ artificial cerebral spinal 
fluid for five minutes before removal of hippocampi. Hippocampi were transferred to a 
McIlwain Tissue Chopper® and slices were cut at 400µM. Slices were then moved into 
ice-cold Slice Culture Media:  8.4g/L MEM Eagle Medium, 20% Horse serum, 1 mM 
GlutaMAX, 1 mM CaCl2, 2 mM MgSO4, 1 mg/L Insulin (dissolved in 0.01 M HCl), 
0.00125% weight/volume Ascorbic Acid solution, 13 mM D-Glucose, 5.2 mM NaHCO3, 
and 30 mM HEPES (pH 7.27-7.28; 320 mmol/kg osmolarity). Slices containing clear 
hippocampal microstructures were isolated in ice-cold slice culture media and 
transferred to 6-well plates containing 1.2 mL/well equilibrated (i.e. incubated in 370C, 
5%CO2 for two hours) slice culture media. A maximum of five slices were plated on cell 
culture inserts (Millicell; Millipore Sigma). Complete media changes were done the first 
day after plating and then every two to three days (for more detail refer to Opitz-Araya 
and Barria 2011). 
4.2.2 Preparation of gene gun bullets for biolistic transfection 
DNA for calcium-calmodulin kinase II (CaMKII) driven green fluorescent protein 
(GFP), wild type GluN2A, GluN2A-P552R, GluN2A-L812M was purified using 
endotoxin-free maxi-prep kits (Qiagen®) with a final concentration of 1-1.5 mg/mL. Prior 
to preparing gene gun bullets, ~30 inches of Tefzel tubbing (Bio-Rad) was dried with N2 
gas (0.4 pressure) for a minimum of 20 minutes. DNA was combined in a 1:1 ratio of 
GFP to GluN2A wild type, or mutant, for a final concentration of 50 µg. This DNA mix 
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was then combined with ~17 mg gold and coated with 100µL 0.05M spermidine. DNA 
was then precipitated with 100µM 1M CaCl2 and washed with 100% ethanol and finally 
dissolved in polyvinylpyrrolidone-ethanol solution to aid in coating the plastic tubing. The 
DNA-gold- polyvinylpyrrolidone-ethanol solution was then injected into the Tefzel tubing 
and allowed to settle for five minutes. The solution was then aspirated off, and the 
remaining DNA-gold mixture was dried with N2 gas (0.4 pressure) for 5 minutes. The 
tubbing was then removed and cut into bullets for loading into the Helios® Gene Gun 
(Bio-Rad). 
4.2.3 Transfection of organotypic slices 
 Slices cultured in vitro for 10 days (DIV 10) were transfected with gene gun 
bullets propelled by helium gas at 100 psi. Slices were either incubated in the presence 
or absence of 50µM memantine beginning four to six hours following transfection. Slices 
were then either fixed in 4% paraformaldehyde for image processing or prepared for 
dual whole or lose-patch recordings three days after transfection.  
4.2.4 Preparation of slides for microscopy 
 Paraformaldehyde was removed from 24-well plates containing hippocampal 
slices and slices were washed three times with HBSS containing Ca2+ and Mg2+ (Life 
Technologies). Slices were then permeabilized in 0.3% Triton X-100 (Sigma-Aldrich) 
and subsequently labeled with Neurotrace (Life Technologies). After a 30-minute 
incubation in Neurotrace, slices were washed three times with HBSS containing Ca2+ 
and Mg2+ and mounted on slides with DAPI Vectaschield mounting medium (Vector 
Laboratories) before being sealed with clear nail polish. Slides were stored in a 40C 
refrigerator until processing. 
4.2.5 Confocal imaging and analysis of organotypic slices  
 Hippocampal slices were imaged using a Zeiss® 880 confocal laser scanning 
microscope (Zeiss LSM 880). Images were obtained at 20x magnification and z-stacks 
were established to have 50% overlap between 0.88µM sections. Z-stacks were 
analyzed by performing a maximum intensity projection (Fiji). The image was then 
converted into a binary bit image by setting the threshold to 2x the background noise. 
Neuronal blebbing was then quantified using the “analyze particles” feature in Fiji. Two 
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measurements were taken using this plug-in feature, the first being the total cell area (0-
infitie µM; circularity 0-1), and the second quantifying neural cell blebbing (3-infitie µM; 
circularity 0.35-1). 
 Percent blebbing was calculated as the ratio of the total blebbing area to the total 
cell area. Only neurons showing at least three branch points were included for analysis. 
Values were plotted using Prism8® (GraphPad) and data were analyzed using one-way 
ANOVA with mutants compared to wild type, followed with a Tukey post-hoc test and 
regarded as significant if p<0.05. 
4.2.6 Dual patch recording and analysis of spike frequency 
 Transfected slices were moved to the recording chamber containing artificial 
cerebrospinal fluid in mM: 125 NaCl, 2.5 KCl, 25 NaHCO3, 1.25 NaH2PO4*H2O, 20 D-
glucose, 2 CaCl2, and 1 MgCl2. Glycine, 3 µM, was added for both dual whole-cell and 
loose-patch recordings, and 10 µM 2-chloroadenosine was added to the artificial 
cerebral spinal fluid for dual whole-cell patch recordings. Solution was perfused at 2.5 
mL/min and synaptic responses were evoked by a monopolar electrode placed to 
stimulate Schaeffer collaterals.  
 For dual whole-cell patch recordings, the internal solution consisted of in mM: 
120 Cs-MeSO3, 15 CsCl, 10 TEA-Cl, 10 HEPES, 8 NaCl, 4 Mg-ATP, 1 MgCl2, 5 QX-
314, 0.3 Na-GFP, and 0.3 EGTA. pH was adjusted by CsOH and the osmolality was 
adjusted to 290 mOsm. Borosilicate glass electrodes were pulled from a P-1000 
Micropipette puller (Sutter Instruments) with resistances of 3 – 5 MΩ. DNQX (10 µM) 
GABAzine (10 µM), MPX-007 (3 and 30 µM), and APV (100 µM ) solutions were made 
the  day of recordings in fresh artificial cerebral spinal fluid. 
For loose-patch recording, artificial cerebral spinal fluid was used to fill electrodes 
with resistances of 2 – 4 MΩ. During the recording, membrane holding current, input 
resistance, and pipette series resistance were monitored. Data were gathered through a 
MultiClamp 700B amplifier (Axon Instruments) using pClamp10 (Molecular Devices), 
filtered at 1 kHz, and digitized at 8 kHz. Data were analyzed using Axograph software 
(axograph.com) and plotted using Prism8 (GraphPad). Statistical significance was 
assessed by using two-tailed Wilcoxon signed rank tests. 
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4.3 Results 
 We began our investigation into neuronal excitotoxicity triggered by GluN2A 
gain-of-function containing NMDA receptors by first assessing cell toxicity in organotypic 
slice culture by measuring blebbing as described in Aim 2. Briefly, we were able to 
direct expression of subunits in excitatory cells by use of plasmids containing green 
fluorescent protein (GFP) or GluN2A subunits, both driven by a calcium-calmodulin 
kinase (CaMKII) promoter. As CaMKII is only expressed in excitatory neurons (Jones et 
al., 1994; Wang et al., 2014), we were able to ask whether expression of mutated 
GluN2A subunits mediate excitotoxicity in cultured CA1 pyramidal neurons from 
organotypic hippocampal slice. Mature slices, equivalent to postnatal 20-21 (P20-21) 
day old mice, were dissected at P7-8, transfected at day in vitro 10 (DIV 10), and fixed 
for imaging, or used in recordings, on DIV 13 (Figure 4.1A).  
Organotypic slices transfected with GFP alone and GFP with GluN2A-P552R 
subunits showed similar blebbing in the absence (GFP = 12.8 ± 3.5%; GFP + GluN2A-
P552R = 10.5 ± 1.6%) and presence of 50 µM memantine (GFP = 8.59 ± 2.4%; GFP + 
GluN2A-P552R = 10.3 ± 1.3%). These results suggest that in organotypic CA1 
pyramidal cells, the presence of GluN2A-P552R subunits is not toxic compared to 
control GFP transfected cells. Similarly, GFP and GluN2A-WT transfected cells treated 
with memantine showed similar cell blebbing (GFP + GluN2A-WT = 10.9 ± 0.3%), 
though more data need to be collected to elucidate a difference between cells 
transfected with GFP and GFP + GluN2A-WT in the absence of memantine. 
  Unlike cells transfected with GluN2A-P552R, GluN2A-L812M transfected cells 
showed significant blebbing (Figure 4.1B-D) (GFP + GluN2A-L812M 32.3 ± 12%; two-
way ANOVA with Tukey post-hoc test, p < 0.05). Blebbing in cells transfected with 
GluN2A-L812M was rescued with 50 µM memantine incubation (GFP + GluN2A-L812M 
7.90 ± 2.1%), suggesting that toxicity is due to aberrant NMDA receptor signaling. 
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Seeing that expression of GluN2A gain-of-function mutants do not consistently 
cause blebbing (i.e. cytotoxicity), we sought to characterize a possible link to neuronal 
hyperexcitability by assessing properties of synaptic transmission. We hypothesized 
that hyperexcitability could manifest as increased action potential firing in neurons with 
expression of GluN2A gain-of-function mutants. To isolate signaling differences without 
perturbing the intrinsic properties of neurons, we evaluated neuronal firing frequency by 
loose-patch recordings. Loose-patch recordings entail electrophysiological assessment 
of the ionic environment just outside of the cell membrane, therefore leaving the internal 
cellular composition intact.  
Due to intrinsic cell-by-cell variability among cultured slices, we assessed 
simultaneous dual-patch recordings to accurately tease apart differences in signaling in 
a neuron transfected with GluN2A gain-of-function mutants compared to a neighboring 
Figure 4.1: Characterization of blebbing in aged organotypic hippocampal 
slices. A) Timeline of organotypic slice preparation. Slices are aged to reflect P20-
21 day old mice. B) Representative image of CA1 pyramidal cells transfected with 
GFP and GluN2A-L812M in the absence and C) presence of 50 µM memantine. D) 
Summary plot of neurite blebbing in CA1 pyramidal cells of transected organotypic 
slices. Data are mean ± SEM from 3-13 neurons. *Indicates significantly different 
(p<0.05 two-way ANOVA corrected for multiple comparisons with a Tukey post-hoc 
test). 
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un-transfected control neuron (Figure 4.2A). We found that GluN2A-WT or mutant 
transfected CA1 pyramidal cells did not show significantly different signaling properties 
compared to un-transfected controls (Figure 4.2 B-E) (p > 0.05 Wilcoxon paired signed-
rank test). This suggests that expression of GluN2A-WT, GluN2A-L812M, or GluN2A-
P552R do not cause hyperexcitability in CA1 pyramidal cells as measured by action 
potential firing in organotypic slices.  
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We speculated that transfection of GFP or GluN2A subunits may cause synaptic 
alterations that could perturb accurate delineation of signaling differences between 
transfected and un-transfected cells. To evaluate this possibility, we measured evoked 
excitatory post-synaptic currents (EPSCs) in dual whole-cell patch recordings 
comparing un-transfected with GFP, or GFP + GluN2A transfected cells (Figure 4.3). 
With our preliminary data, we see that transfection does not alter synaptic signaling 
properties (Figure 4.3). 
 
Figure 4.1: Neuronal firing rates in transfected organotypic slice. A) 
Representative image illustrating electrode placement in the CA1 region of the 
hippocampus. B) GluN2A-WT, C) GluN2A-L812M, D) GluN2A-P552R firing 
frequency plotted against un-transfected cell firing frequency. E) Summary plot 
illustrating that GluN2A gain-of-function mutations had no significant effect on firing 
frequency compared to un-transfected controls, summary plot. Data are mean ± SEM 
from 3-8 slices.  
 
Figure 4.3: Evoked synaptic transmission properties in transfected organotypic 
slice. A) Schematic illustrating stimulating and dual whole-cell patch clamp electrode 
placement. Adapted from Chen et al., 2012. B & D) AMPA receptor elicited currents 
measured at -60mV and NMDA receptor responses measured at +40mV (C & E) in 
baseline (black), 3 µM MPX-007 (green), 30 µM MPX-007 (red), and 100 µM APV 
(blue). Un-transfected cells (UT) are shown on top and simultaneous dual whole-cell 
patch of GFP (B-C) and GluN2A-WT (D-E) transfected slices are represented in the 
bottom panels.  
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The preliminary data presented in this aim provide no clear evidence that 
GluN2A gain-of-function mutants mediate neuronal excitotoxicity. While transfection of 
GluN2A-L812M subunits caused neuronal blebbing, which could be rescued with 
memantine, we did not see a difference in neuronal firing, a canonical measure of 
excitability. Furthermore, these was no indication that expression of GluN2A-P552R 
subunits cause cell blebbing, a hallmark of impeding cell death, or abnormal signaling in 
transfected CA1 pyramidal cells in organotypic slices. We also did not observe 
interferences in synaptic signaling, assessed by the NMDA receptor mediated EPSC 
time course, upon transfection (Figure 4.3). These preliminary data suggest that 
excitotoxicity is not the sole determinant of aberrant neuronal signaling properties 
caused by NMDA receptors harboring GluN2A gain-of-function mutations. 
4.4 Discussion 
Here we sought to determine whether select GluN2A gain-of-function mutations 
mediate excitotoxicity or hyperexcitability in CA1 pyramidal cells in mature organotypic 
slices. NMDA receptors harboring GluN2A gain-of-function mutations are more easily 
activated, for example due to increased agonist potencies or relief of tonic endogenous 
Mg2+ inhibition. Therefore, it is conceivable that deleterious outcomes seen in children 
with epilepsy-aphasia spectrum (EAS) disorders result from NMDA receptor-induced 
excitotoxicity. In this study, we assessed excitotoxicity by evaluating neural blebbing 
and measuring firing frequency in aged organotypic hippocampal slices. 
The hippocampus is an important region for establishing declarative memories, 
which are memories that form based on associative sensory experience (Review 
Dumas, 2005). Children with (EAS) disorders often present with difficulties in speech 
output and understanding, a process involving declarative memory processing. With this 
in mind, we assessed excitotoxicity in the hippocampus due to its involvement in EAS 
disorders and declarative memory formation.  
 Extent of excitotoxicity was assessed by quantifying neurite blebbing, a 
consequence of excitotoxicity, and hyperexcitability was assessed by measuring 
neuronal firing frequency in mature organotypic slices. The slices were effectively aged 
 65 
at 20-21 days because they were isolated from postnatal day 7-8 (P 7-8) mice and 
grown in culture for a total of 13 days. By the third week after birth, the developmental 
switch from GluN1/GluN2B diheteromer NMDA receptors to NMDA receptors that also 
contain GluN2A subunits (e.g. GluN1/GluN2A/GluN2B triheteromers) is well underway 
in rodents (Monyer at al., 1994; Sheng et al., 1994). It is during this developmental 
switch in humans that the GluN2A-mediated severe EAS begins to manifest in children.  
We found that transfection of GluN2A-L812M, but not GluN2A-WT or GluN2A-
P552R subunits caused neural blebbing, a known consequence of excitotoxicity (Figure 
4.1). Furthermore, blebbing seen in neurons expressing GluN2A-L812M could be 
rescued with incubation of 50 µM memantine, a non-selective NMDA receptor 
antagonist. These data indicate that NMDA receptors harboring GluN2A-L812M 
subunits mediate excitotoxicity in CA1 pyramidal neurons. 
Memantine has shown clinical efficacy in treatment of a patient harboring the 
GluN2A-L812M mutation (Pierson et al., 2014). This patient developed severe 
continuous spike-wave during slow wave sleep seizure activity with multiple seizures 
daily. The patient exhibited refractory epilepsy and had been administered lacosamide, 
rufinamide, and valproic acid without seizure resolution (mg/kg per day: lacosamide 
11.25; rufinamide 45; valproic acid 25). Upon administration of memantine (~0.5mg/kg 
daily), seizure frequency reduced to 3 per week and myoclonic jerks dissipated 
completely. No cognitive differences were apparent after memantine treatment. The 
amelioration in symptom progression in this patient with the GluN2A-L812M mutation is 
consistent with our data showing that GluN2A-L812M subunit-induced hippocampal 
excitotoxicity could be rescued with memantine. 
Our finding that GluN2A-L812M, but not GluN2A-P552R expression, caused 
significant blebbing in hippocampal pyramidal cells suggest that excitotoxicity is not the 
sole determinant of the symptoms observed in the EAS patients. It is possible that 
different mutations mediate excitotoxicity to different cell types (i.e. excitatory vs 
inhibitory neurons) and future experiments should assess excitotoxicity in distinct cell 
types. Thus, we deduce that excitotoxicity resulting from NMDA receptors harboring 
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GluN2A gain-of-function mutations does not fully describe the pathologies associated 
with EAS. 
 Another potential outcome of the GluN2A gain-of-function mutations could be 
hyperexcitability, which could lead to increased seizure activity. This possibility was 
evaluated by assessing aberrant increases in firing frequency. Neuronal 
hyperexcitability in CA1 pyramidal cells may be accompanied by excitotoxicity, but the 
two potential consequences of GluN2A gain-of-function mutations are not necessarily 
always directly linked. Since approximately 90% of patients with GRIN2A mutations 
present with seizure disorders (XiangWei et al., 2018), we sought to characterize 
abnormal firing frequency in organotypic slices transfected with GluN2A-L812M or -
P552R subunits compared to GluN2A-WT controls. Interestingly, we found no 
significant difference between GluN2A gain-of-function in transfected slices compared 
to GluN2A-WT transfected slices (Figure 4.2). This further suggest that neither 
excitotoxicity nor hyperexcitability in pyramidal cells are the predominant mechanisms of 
disease pathology for patients harboring GluN2A gain-of-function mutations.  
 However, it is possible that biolistic transfection alters synaptic properties. Under 
this assumption, we would not be able to delineate a difference between GluN2A gain-
of-function and GluN2A-WT transfections due to general synaptic dysfunction resulting 
from transfection. In order to assess this possibility, we evaluated evoked excitatory 
post-synaptic currents (EPSCs) in dual whole-cell patch recordings. Our preliminary 
data indicate that synaptic properties are unaltered in both GFP and GFP + GluN2A-WT 
transfected cells compared to un-transfected cells (Figure 4.3). We assessed AMPA 
receptor activation at negative holding potentials and NMDA receptor activation at 
positive potentials and saw no difference in simultaneous recordings of un-transfected 
cells. We were also able to measure MPX-007 mediated inhibition, which was fully 
recapitulated in transfected and un-transfected cells, indicating the presence of synaptic 
GluN2A-containing NMDA receptors (Figure 4.3). 
 Here, we conclude that in our experimental conditions there is no evidence for 
GluN2A gain-of-function induced excitotoxicity or hyperexcitability in CA1 pyramidal 
cells. While GluN2A-L812M transfected CA1 pyramidal neurons showed cell blebbing 
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that was reduced with memantine, dual-patch recordings did not demonstrate 
excitotoxic neuronal signaling. Furthermore, cells transfected with GluN2A-P552R 
subunits did not show differences in neurotoxicity or signaling. If excitotoxicity or 
hyperexcitability are the primary drivers of disease pathology, then we would expect to 
see some indications of these phenotypes following expression of the severe GluN2A 
gain-of-function mutants in CA1 pyramidal cells. We have not consistently seen this, 
indicating that the disease pathology is more nuanced. Interestingly, our data are in 
agreement with the finding that GluN2A loss-of-function mutants also cause EAS 
disorders, including seizures, which cannot be canonically explained by straightforward 
excitotoxicity or hyperexcitability of pyramidal cells.  
Future experiments should quantify the extent and localization of GluN2A gain-
of-function subunits in different cell types to determine if pathology is specific to 
particular cell types, or if these subunits are trafficked to the cell surface or synapse. 
Additionally, since seizures only occur during slow-wave sleep, it would be prudent to 
assess the dependence of seizure activity in relation to slow-wave oscillations. 
Furthermore, as kids with EAS are unable to solidify verbal learning and memory, it 
would be interesting to quantify possible differences in long-term potentiation or 
depression and episodic memory retention. The contribution of GluN2A gain-of-function 
mutants in these physiological processes could elucidate foundations for cognitive 
impairment seen in kids with severe EAS. 
5.0 General Discussion 
 In this body of work, we have characterized GluN2A-selective negative allosteric 
modulation of NMDA receptors harboring GluN2A gain-of-function mutations and 
assessed GluN2A gain-of-function mediated links to excitotoxicity and hyperexcitability 
in excitatory neurons. We assessed GluN2A gain-of-function mutations identified in 
children with epilepsy-aphasia spectrum (EAS) disorders, of varying severity. We 
selected six mutations with disparate domain localization in NMDA receptors, including 
mutations in the agonist binding domain (ABD), transmembrane domain (TMD), and 
linker regions between the ABD and TMD (Figure 2.2). 
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 Out of the six representative GluN2A gain-of-function mutants, all but one 
showed increases in both glycine and glutamate potencies (Figure 2.2). The GluN2A-
N615K mutant is insensitive to tonic inhibition by endogenous Mg2+, but does not alter 
agonist or co-agonist potencies, or sensitivities to other endogenous modulators Endele 
et al., 2010). Therefore, this mutant served as a positive control in our experiments as it 
behaves like GluN2A-wild type (GluN2A-WT) containing NMDA receptors in terms of 
agonist potencies and deactivation time course. 
 Since NAM mediated inhibition acts to destabilize glycine binding (Figure 2.5), it 
was unknown whether NAMs could overcome increases in glycine potency seen in 
NMDA receptors with GluN2A gain-of-function mutations. Despite upwards of 10-fold 
increases in glycine potency, NAMs were still able to inhibit NMDA receptors containing 
GluN2A gain-of-function mutations (Figure 2.3). Decreased sensitivity to NAM inhibition 
was highly correlated to increases in glycine potency for all mutants except for NMDA 
receptors harboring GluN2A-P552R mutations (Figure 2.4). 
 To investigate the discrepancy in GluN2A-P552R mutant sensitivity to NAM-
mediated inhibition, we calculated the NAM binding affinity (KB) and allosteric constant 
(α) for a subset of the GluN2A gain-of-function mutations, including GluN2A-P552R. We 
evaluated glycine concentration-response curves in the increasing presence of NAM 
(TCN-201) and performed Schild analysis to determine potential differences in KB or α. 
Again, GluN2A-N615K served as our positive control and showed no alterations in KB or 
α compared to GluN2A-WT values. Similarly, as expected GluN2A-L812M containing 
NMDA receptors showed no significant differences in KB or α compared to GluN2A-WT 
values. Interestingly, GluN2A-P552R containing receptors showed a 10-fold decrease in 
KB, indicating that this mutation changes the dimer interface where NAMs bind (Figure 
2.6).  
 We next sought to determine whether NAMs were effective at inhibiting NMDA 
receptors containing GluN2A gain-of-function mutations under synaptic-like events. 
Glutamate is released from presynaptic sites and persists in the synaptic cleft for a few 
milliseconds (~3-5 ms; Clements et al., 1992) before being removed by glutamate 
transporters (Danbolt, 2001). We mimicked this physiological glutamate time course 
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with HEK293 cells transfected with GluN1A and GluN2A gain-of-function mutants to 
determine NAM mediated inhibition under non-steady state kinetics.  
 We assessed extent of NAM inhibition in both low and mid-range physiological 
glycine levels (i.e. 3 and 10 µM glycine). Surprisingly, despite increases in glycine 
potency measured during steady-state conditions in Xenopus oocytes, non-equilibrium 
responses did not reflect a significant increase in glycine potency (Figure 2.8), except 
for NMDA receptors containing GluN2A-P552R mutations. This disparity in equilibrium 
and non-equilibrium potencies could reflect the absence of NMDA receptor 
desensitization in our recapitulated synaptic-like time course. 
 During NMDA receptor desensitization, the channel closes but agonists remain 
bound. In this state, increases in agonist potency could result from increased agonist 
occupancy when the channel re-enters states that allow for channel opening (Figure 
2.9). However, during synaptic-like activation in HEK293T cells, NMDA receptor 
desensitization is minimized and thus the state-mediated effects on agonist potency are 
virtually eliminated. This phenomenon could reflect the apparent decreases in agonist 
potency in non-equilibrium vs steady-state responses. Along these same lines, we 
found that NAMs were more effective at inhibiting NMDA receptors containing GluN2A 
gain-of-function mutations under synaptic-like activation (Figure 2.8).  
Seeing as some NMDA receptors harboring GluN2A gain-of-function mutations 
show increased agonist potencies (Figure 2.2) and slowed deactivation kinetics (Figure 
2.7), we postulated that excitatory neurons transfected with these mutants would show 
signs of excitotoxicity. We first evaluated excitotoxicity in mature cortical neurons 
transfected with green fluorescent protein (GFP) and either GluN2A-WT or GluN2A 
gain-of-function mutants driven by a calcium-calmodulin kinase (CaMKII) promoter. 
CaMKII is selectively expressed in excitatory neurons, which allowed us to target our 
excitotoxicity hypothesis directly to excitatory neurons. Furthermore, we chose to assay 
GluN2A subunits with mutations in the TMD or linker regions because mutations located 
in these domains are associated with the more severe phenotypes documented in EAS, 
including both grey and white matter atrophy (Strehlow et al., 2018). 
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We found that neurons transfected with GluN2A-P552R, GluN2A-N615K, and 
GluN2A-L812M subunits did not show pronounced neurite blebbing, a symptom of 
excitotoxicity, as compared to GluN2A-WT transfected controls (Figure 3.1). While 
GluN2A-L812M transfections showed statistically significant blebbing compared to 
GuN2A-WT transfections, the amount of blebbing was minimal (2.8%). This was 
surprising seeing as these same mutations are associated with epileptic 
encephalopathy in humans (Endele et al., 2010; Strehlow et al., 2018; Pierson et al., 
2014; Yuan et al., 2014; Ogden et al., 2017). Together, these data indicate that EAS 
resulting from GluN2A gain-of-function mutations is more complicated than simply 
arising from excitotoxicity.  
To rule out other contributions of GluN2A gain-of-function mutations to 
excitotoxicity, we also assessed neural blebbing in CA1 hippocampal cells of 
organotypic slices (Figure 4.1). The hippocampus is involved in establishing declarative 
memories, which are learned, associative memories (Review – Dumas, 2005). Verbal 
associative memory formation is drastically impaired in children with EAS and therefore 
we speculated that hippocampal cells may be more sensitive to NMDA receptors 
harboring GluN2A gain-of-function mutations.  
Similar to our results seen in cortical neurons, transfection of mature 
hippocampal cells resulted in significant blebbing from GluN2A-L812M transfections, but 
not from GluN2A-P552R expression. Furthermore, the blebbing seen in neurons 
transfected with GluN2A-L812M could be rescued by incubation with memantine, a non-
selective NMDA receptor antagonist. Benefits of memantine exposure have been 
documented in a patient with the GluN2A-L812M mutation, which correlates well with 
our neuron data (Pierson et al., 20414). Memantine treatment was able to drastically 
reduce seizure frequency from multiple times a day to approximately 3 per week in a 
patient with the GluN2A-L812M mutation. 
However, not all GluN2A gain-of-function mutations caused excitotoxicity in cell 
culture (Figures 3.1 and 4.1), despite the severity of disease associated with these 
mutations. This indicates that disease severity is not exclusively based upon 
excitotoxicity caused by these mutations. Alternatively, the excitotoxicity could be more 
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apparent in other cell types, such as inhibitory interneurons. If interneurons are 
selectively eliminated to excitotoxicity, disparities in the excitatory/inhibitory balance, 
along with network oscillations could contribute to seizure propagation. Future studies 
should investigate GluN2A gain-of-function mutant effects in interneurons. 
It is possible that these mutated GluN2A subunits are not efficiently trafficked to 
the surface and/or the synapse. Indeed, some mutants have documented decreases in 
cell surface expression, which essentially results in a loss-of-function phenotype (Ogden 
et al., 2017). Interestingly, both GluN2A gain and loss-of-function mutations are 
associated with EAS disease etiology. Future studies should address this possibility and 
quantify cell surface expression for GluN2A gain- and loss-of-function mutants.  
While we did not see excitotoxicity evaluated by neural blebbing, we postulated 
that hyperexcitability could be apparent in neuronal signaling properties. Seeing as 
approximately 90% of individuals with mutations in GluN2A present with epilepsy 
(XiangWei et al., 2018), we hypothesized that neurons transfected with GluN2A gain-of-
function mutations would show aberrant firing due to hyperexcitable neurons. 
To determine differences in neuronal signaling, we transfected mature 
organotypic slices with GFP and either GluN2A-WT, GluN2A-P552R, or GluN2A-L812M 
subunits. We performed dual loose-patch recordings as to avoid disrupting internal 
properties of the neurons and to control for inherent variability in cell signaling 
properties identified in slice culture. We found that neurons transfected with GluN2A-WT 
or gain-of-function mutations did not show significantly different signaling properties 
from un-transfected cells recorded in the same slice.  
It is possible that biolistic transfection of slices causes detriments in synaptic 
signaling, which would occlude accurate delineation of signaling properties between 
transfected conditions. Therefore, we also assessed conservation of excitatory post-
synaptic currents (EPSCs) in dual-whole cell patch clamp experiments (Figure 4.3). We 
did not see an effect of transfection when comparing neurons transfected with either 
GFP or GFP with GluN2A-WT subunits with un-transfected controls in the same slice. 
This indicates that synaptic properties are conserved in biolistic-transfected slices. 
Albeit, future experiments are required to determine if GluN2A subunits with gain-of-
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function mutations are trafficked to the synapse and affect NMDA receptor-mediated 
EPSCs by slowing the decay time course. 
Together, these data provide no clear evidence that GluN2A gain-of-function 
mutations mediate pronounced excitotoxicity measured by both neural blebbing or 
mediate hyperexcitability in excitatory neurons. While unexpected, these data are better 
understood in light of GluN2A loss-of-function mutations that also cause EAS disorders 
with similar seizure activity as compared to GluN2A gain-of-function mutations. 
Therefore, the etiology of NMDA receptor dysfunction resulting from mutated GluN2A 
subunits is more nuanced than simply propagating due to unrequited excitotoxicity and 
hyperexcitability of pyramidal cells. A more subtle model of poor signal integration may 
serve as a better foundation to describe the etiology of EAS disorders involving 
mutations in GRIN2A. Since NMDA receptors coordinate neuronal firing with sensory 
experience, any disruption in this system could manifest as deficits in declarative 
memory.  
Future studies should narrow down the plethora of avenues that could cause 
aberrant wiring due to NMDA receptors containing gain- or loss-of-function GluN2A 
subunits. Interneurons, rather than excitatory neurons, could be the primary targets of 
GluN2A-mediated malfunction. In this case, interneurons harboring essentially loss-of-
function GluN2A subunits could tilt the excitatory/inhibitory balance towards 
excitotoxicity due to a loss in inhibitory tone. Or rather, it is possible that these subunits 
are not efficiently trafficked to the membrane in all cell-types, and therefore also present 
as loss-of-function mutants. Future studies should focus on teasing apart these 
attributes so that we can gain a better understanding of GRIN2A mutation involvement 
in EAS disorder pathology. 
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